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Abstract 
Bleomycin has been used successfully in the treatment of haemangioma, keloid and 
vascular malformation; however the mode of action of this chemotherapeutic drug on 
these non-malignant dysplasias is not well understood. The aim of this study was to 
investigate the effects of bleomycin on a range of human primary cell lines to improve 
our understanding of the mechanism by which bleomycin exerts its effects. This may 
facilitate the subsequent identification of alternative therapeutic strategies, thereby 
avoiding the well recognised and potentially life threatening side effects associated with 
the use of bleomycin. Primary cell lines were isolated from excised lesions using an 
explant culture technique. The cell lines thus obtained, along with other cell lines 
previously derived from other tissues, were exposed to a range of concentrations of 
bleomycin to examine dose response. Results showed that at a dose of lOOmU/ml 
bleomycin, all cell lines underwent a Gl arrest after 48 hours in culture. At higher 
doses, bleomycin induced a dose-dependent increase in the proportion of cells in sub-
Gl with all cell lines treated, a specific marker of apoptosis. Bleomycin induced 
apoptosis was further confirmed by TUNEL assay and results showed that keloid 
derived cells had a significantly greater level of DNA strand breaks than foreskin 
fibroblasts. An antibody specific for cleaved caspase-3 was also used to investigate 
apoptosis initiation. Both keloid derived cells and foreskin fibroblasts showed a 
bleomycin-induced cleavage of caspase-3, however the level of caspase-3 cleavage was 
significantly greater in keloid derived cells. In conclusion, results from this study show 
that bleomycin induces apoptosis of haemangioma, venous malformation and keloid 
derived cells in a dose dependent manner. In addition, this study reports for the first 
time that bleomycin induces a caspase-3 mediated apoptotic cell death in keloid derived 
cells. 
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Introduction 
Chapter 1 
1 Introduction 
1.1 Bleomycin 
A number of antibiotic cancer therapeutics were discovered in the middle of the 20'*' 
century through screening of bacterial filtrates for anti-cancer activity. Examples 
include neomycin (Waksman et al. 1949), adriamycin (Arcamone et al. 1969) as well as 
bleomycin. The first report of the isolation of the latter, fi-om the bacterium 
Streptomyces verticillus was published by Umezawa et al. (1966). Bleomycin was 
shown to inhibit the growth of Escherichia coli and HeLa cells in vitro, and was found 
to have inhibitory activity against Ehrlich carcinoma, sarcoma 180 and other 
transplantable mouse ascites tumours (Umezawa et al. 1966; Umezawa et al. 1968; 
Takeuchi et al. 1968). These studies led to clinical trials evaluating the use of bleomycin 
in the treatment of a range of human malignancies, including squamous cell carcinomas 
of the skin, head and neck, oesophagus, lung and cervix, as well as testicular neoplasms, 
melanoma and Hodgkin's lymphoma. 
1.1.1 Pharmacological effects of bleomycin 
Bleomycin has been described to have at least two modes of action: direct cytotoxicity 
by means of DNA degradation (Burger et al. 1981), and cell cycle arrest (Barlogie et al. 
1976). 
Bleomycin-mediated DNA degradation requires the presence of a redox-active metal 
such as Fe'^ ^ as well as molecular oxygen derived fi-om O2 (Burger et al. 1981) to form 
activated bleomycin and Fe^ "^  hydroperoxide. This can then bind to DNA, with the metal 
binding domain located in the minor groove and the bithiazole group intercalated into 
the double helix (Sanz et al. 2002). This induces the formation of single and double-
strand breaks in a sequence specific fashion. 
In addition to DNA cleavage, bleomycin has been shown to block the cell cycle at G2 in 
a concentration and exposure time-dependent manner (Barlogie et al. 1976) and degrade 
cellular RNA (Carter et al. 1990). Bleomycin also induces apoptosis, which is though to 
be another of its antitumour properties. Bleomycin is known to induce apoptosis in 
vitro; Tounekti et al. (1993) demonstrated bleomycin induced apoptosis in Chinese 
hamster lung fibroblasts identified by fluorescence activated cell cycle analysis, DNA 
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fragmentation and morphological analysis. Hamilton et al. (1995) found a bleomycin 
dose-dependent induction of apoptosis in human alveolar macrophages in vitro, as 
determined by increased DNA fragmentation and DNA ladder formation. Vemole et al. 
(1998) also demonsfrated bleomycin-induced apoptosis in human lymphocytes, as 
detected by cell cycle analysis and detection of DNA sfrand breaks. Although these 
studies all detected apoptosis, the exact mechanism by which bleomycin exerts its 
apoptotic effect remains elusive. 
Clinically, the main dose-limiting toxicity of bleomycin is exerted on the lung 
(Yamamoto 2006). Bleomycin has been shown to produce interstitial pulmonary 
fibrosis in humans (Weiss et al. 1980; Chandler et al. 1990; Jules-Elyse et al. 1990) as 
well as in experimental models (Hagimoto et al. 1997). Pulmoneiry fibrosis is 
characterised by excessive synthesis and deposition of extracellular matrix (ECM) in the 
distal airspace (Higashiyama et al. 2007). Although lung fibrosis is the main dose-
limifing toxicity, bleomycin appears to have additional effects on the vascular system 
and cutaneous toxicity has also been described. 
1.1.2 Effects of bleomycin on the vascular system 
The first report of the antiangiogenic properties of bleomycin was by Oikawa et al. in 
1990. Their work using chick embryos showed that bleomycin inhibited embryonic 
angiogenesis in a dose-dependent manner. These observations were confirmed by 
Lincun and Gongjja in 2000, using Pingyanmycin, the active component of which is 
Bleomycin. Their work demonsfrated the antiangiogenic effect in chick embryos and on 
the basis of these findings, proceeded to treat 14 children with haemangiomas by means 
of intralesional injection. Nearly all patients showed complete regression following less 
than three topical injections of Pingyanmycin. In 2001, Gao et al. set out to investigate 
the mechcinism of Pingyanmycin sclerotherapy, by injecting the posterior auricular 
veins of rabbits with the drug. Their work described damage to the vascular 
endothelium immediately after injection, followed by endothelial and smooth muscle 
cell proliferation after 7 days, and finally vessel occlusion occurred at 21 days following 
injection. 
Bleomycin is a widely used antineoplastic agent for the treatment of malignant pleural 
effusions; it's mechanism of action is believed to be as a chemical sclerosant similar to 
talc or tetracycline (Antunes et al. 2003). It was noticed that in the treatment of pleural 
effusions, bleomycin caused fibrosis and inflammation. So in 1977, Yura et al. were the 
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first to try bleomycin solution as a sclerosing agent for the treatment of cystic hygroma. 
Later work by Tanigawa et al. showed that using bleomycin in the form of microsphere 
in oil emulsion, improved the confinement of this drug and enhanced its activity in the 
treatment of cystic hygroma and lymphangioma. Work by Mathur et al. (2005) used 
bleomycin sclerotherapy as a first line management on ten children presenting with 
either congenital lymphatic or vascular malformations. After intralesional 
administration of bleomycin, the size of the lesions reduced by 50% or more in seven 
patients, with three showing complete or near complete response. In a larger study, 
involving 95 patients, the effectiveness of intralesional bleomycin injection for the 
treatment of haemangiomas and vascular malformafions was evaluated (Muir et al. 
2004). Complete resolution or significant improvement occurred in 80% of all patients 
treated, with complete resolution observed in almost half of the pafients presenting with 
haemangioma. These data suggest that bleomycin may have a role to play in the control 
of vascular dysplasias, specifically infantile haemangioma and vascular malformations, 
but also demonstrate a relafive lack of understanding of the mechanism by which it 
exerts its effect in these lesions. 
1.1.3 Cutaneous side effects of bleomycin 
Various cutaneous side effects have been described following bleomycin treatment, 
including flagellate erythema, hyperpigmentafion, scleroderma, alopecia, gangrene and 
nail dystrophy (Duhra et al. 1991; Kerr et al. 1992; Siegel et al. 1990; Elomaa et al 
1984; Miller 1984). Bleomycin was shown to be effective in the treatment of 
keratocanthomas (Sayama et al. 1983) and recalcitrant warts (Shumack et al. 1979). 
These data prompted a study to investigate the effectiveness of bleomycin treatment for 
keloid and hypertrophic scars (Bodokh et al. 1996). This French study involving 36 
patients; 31 of which had keloid and 5 of which had hypertrophic scars, showed that 
after administering 3-5 intralesional injections of bleomycin complete regression was 
observed in 69.4%» of the lesions. Another study was published in 2001, involving 13 
patients; 6 with hypertrophic scars and 7 with keloids (Espana et al. 2001). In this study 
bleomycin was dripped onto the scars and multiple punctures were made by a 25-gauge 
needle. In response to this treatment they observed complete flattening in 6 cases, 
highly significant flattening in 6 cases and significant flattening in 1 case. In 2005, a 
study was performed involving 14 patients; 12 keloid and 2 hypertrophic scars, whose 
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lesions had not responded to intralesional steroid injection. Multiple jet-injections of 
bleomycin were administered to each lesion and injections were repeated each month. 
After the treatment 11 lesions showed complete flattening, 1 showed highly significant 
flattening and two showed significant flattening (Saray et al. 2005). Most recently, a 
study by Aggarwal et al. (2008) involved 50 patients with keloid and hypertrophic scars, 
administering bleomycin through the multiple puncture technique. Complete flattening 
was observed in 44% of cases. Although results from these trials are promising, further 
double blind, placebo controlled studies would be necessary to confirm the efficacy of 
bleomycin in the treatment of these scars. Again, as with lymphatic and vascular 
lesions, the mechanism of action is incompletely understood. 
1.2 Vascular Malformations 
1.2.1 General 
Vascular anomalies were classified on the basis of their endothelial characterisfics by 
Mulliken and Glowaki in 1982, into haemangioma and vascular malformations. 
Vascular malformations can be arterial, capillary, venous or lymphatic and are a 
collection of abnormal vessels with normal mast cell count and endothelium (Marthur et 
al. 2005). Vascular malformafions are present at birth, enlarge in proportion to the 
growth of the individual and never regress spontaneously (Donnelly et al. 2000; 
Marthur et al. 2005). Vascular malformations can be further divided into high flow or 
low flow lesions - those involving arterial components are termed high-flow lesions, 
such as arteriovenous malformafions (AVM) and arteriovenous fistulas (AVF). AVMs 
are characterised by abnormal connections between veins and arteries. Although present 
at birth, they are often exacerbated during puberty or pregnancy (Kouhout et al. 1998). 
Low flow vascular malformations include primarily venous, lymphatic and mixed 
malformafions (Donnelly et al. 2000). Lymphafic malformations are abnormally formed 
lymphafic channels, which can occur in any locafion, although most are located in the 
head and neck region. Histologically, they present as thin walled fluid-filled cysts with 
surrounding connecfive fissue (Blei et al. 2005). The exact cause of lymphatic 
malformafions is not entirely understood; however it is thought that they arise due to 
abnormal development during embryonic lymphangiogenesis (Breier 2005). 
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1.2.2 Treatment of Vascular Malformations 
Current therapies for lymphatic malformations include sclerotherapy and surgical 
resection. Current treatment for vascular malformafions include surgery to remove the 
abnormal vessel tissue or embolisafion with various agents such as absolute ethanol, 
glue or polyvinyl particles. Risk of excessive bleeding during and after surgical excision 
is high, due to the vascular nature of these lesions. Another draw back of surgical 
excision is the high recurrence rate of these lesions (Lee at al. 2004). The agents used in 
embolisation can be toxic, for example i f large amounts of absolute ethanol enter the 
systemic circulafion, this can cause damage to the central nervous system. Other major 
complications associated with ethanol embolisation include infection, acute renal failure 
and brain infarct; minor complications include skin necrosis, nerve injury and blistering 
(Do et al. 2005). Intralesional bleomycin injection has been successfully used in the 
treatment of vascular malformations, with a complete resolution in 32% of cases and 
significant improvement in 52% of cases of venous malformations (Muir et al. 2004). 
These preliminary studies suggest that bleomycin is effective; however randomised 
controlled trials would be required to confirm these effects. 
1.3 Infantile Haemangioma 
1.3.1 General 
Infantile haemangiomas are benign vascular proliferafions and are the most common 
tumour of infancy (Chiller et al. 2002). They occur more fi-equently in Caucasian infants 
than other racial groups and female infants are more likely to develop haemangioma 
than males (Chiller et al. 2002). Typically, they are not present at birth, but present 
within the first few weeks of life. In contrast to vascular malformations, which grow 
proportionately with an individual, haemangiomas display 3 unique growth phases. The 
proliferative phase is characterised by abundant immature endothelial cells (Yu et al. 
2004) angiogenesis and clonal expansion of endothelial cells (Boye et al. 2001). The 
rapid proliferative phase is followed by a slow spontaneous involuting phase, 
characterised by endothelial-lined vascular channels and endothelial cell apoptosis and 
finally the involuted phase by an increase in adipocytes and accumulation of fibrofatty 
tissue (Yu et al. 2006). 
The precise cause of infantile haemangioma remains unknown. In 2000, a study by 
North et al. suggested a relationship between infantile haemangioma and placental 
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tissue, by identifying GLUT-1 positive staining of infantile haemangiomas. GLUT-1 is 
not expressed by other vascular lesions, making the identification of this marker a 
valuable tool for diagnosis. An investigation into cell morphology and protein 
expression of haemangioma endothelial cells showed that the cells were more 
characteristic of embryonic microvascular endothelial cells, further supporting the 
hypothesis that haemangiomas arise from residual angioblast tissue that is undergoing 
delayed proliferation and remodelling (Dosanjh et al 2000). 
Both extrinsic and intrinsic defects have also been proposed as the cause of 
haemangioma. Bielenberg et al. (1999) proposed that the expansion of endothelial cells 
in haemangioma was due to an extrinsic defect. Their work found that the epidermis 
overlying proliferating haemangiomas showed altered expression of angiogenic factors 
and suggested that the endothelial cells of these tumours were responding to an aberrant 
exogenous growth signal. The intrinsic defect theory proposes that changes in 
endothelial behaviour in haemangioma may be caused by somatic mutations. Work by 
Boye et al. (2001) showed that haemangioma-derived endothelial cells are clonal and 
exhibit abnormal behaviour. Their findings suggested that haemangiomas are caused by 
a somatic mutation that led to the expansion of a single endothelial cell. This led to the 
hypothesis that endothelial progenitor cells (EPCs) could perhaps be precursors of the 
clonal endothelial cells (Yu et al. 2004). EPC's are precursor cells of vascular 
endothelial cells, which are mobilised from the bone marrow into the peripheral blood 
and are thought to promote neovascularisation by differentiating into mature endothelial 
cells (Zhang et al. 2007). Yu et al. found mRNA encoding CD 133-2 (an important 
marker for EPCs) in proliferating but not involuting or involuted haemangioma, and 
also identified CD 133 and CD34 positive cells by flow cytometry in proliferating 
haemangiomas. The CD 133 gene codes for a pentaspan transmembrane glycoprotein, 
which is thought to fianction in maintaining stem cell properties by suppressing 
differentiation (Entrez Gene PROMl). The CD34 gene codes for a cell surface 
glycoprotein of the same name, which fiinctions as a cell-cell adhesion factor (Krause et 
al. 1996). Their work suggested that EPCs may contribute to early expansion of 
haemangioma. 
In 2008, Khan et al. reported the discovery of less differentiated stem cells in 
haemangioma specimens, which they referred to as haemangioma-derived stem cells 
(HemSCs). HemSCs were isolated from haemangiomas using anti-CD 133 coated 
magnetic beads. These cells were then clonally expanded in vitro and differentiated into 
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multiple lineages, including adipocytes. The clonal HemSCs were implanted into 
immunodeficient mice and were shown to produce haemangioma-like lesions consisting 
o f GLUT-1 positive microvessels. Two months after implantation, this HemSC derived 
lesion was shown to undergo an involutive process by differentiation into adipocytes. 
Their work suggested that this newly identified HemSC is the cellular origin o f infantile 
haemangioma. 
Just as the exact cause o f infantile haemangioma is unknown, little is known about the 
mechanisms that contribute to their spontaneous regression. It was reported that 
mesenchymal stem cells (MSCs) reside in haemangiomas and that these cells would be 
likely precursors o f the adipocytes found in the involuting phase (Yu et al. 2006). It was 
proposed that MSCs are recruited to the site o f haemangioma from the bone marrow 
through the circulation or fi-om nearby MSC niches in the dermis and adipose tissue. 
Once recruited the MSCs would differentiate into adipocytes fol lowing specific cues 
fi-om the microenvironment during the involuting and involuted phases (Yu et al. 2006). 
1.3.2 Treatment of Haemangiomas 
Most haemangiomas are minor birthmarks that require no treatment; however in 
approximately 10% o f cases o f haemangioma, complications occur. These include 
bleeding and ulceration, fiinctional impairment to fiinctions such as such as vision, 
hearing and respiration and larger lesions can divert blood supply and cause high output 
heart failure (Ogino et al. 2001; Haggstrom et al. 2006; Hsiao et al. 2007). Also, the 
psychosocial effects o f cosmetic disfigurement must also be considered. Current 
treatments for infantile haemangioma include corticosteroids, administered either orally, 
topically or intralesionally. Oral corticosteroids in the form o f prednisolone remains the 
most common form o f treatment for infantile haemangiomas (Chan 2007), however this 
treatment has numerous potential side effects including stunting growth, gastrointestinal 
upset, obesity and increased susceptibility to infections. Haemangiomas which have 
failed to respond to corticosteroid treatment are often treated with subcutaneous 
Interferon-alpha-2a (IFN-a-2a) injections. IFN-a-2a is a potent angiogenesis inhibitor 
that acts by blocking the action o f basic fibroblast growth factor (Kumar et al. 2002). 
Adverse effects o f IFN-a-2a therapy include fever, nausea, fatigue, malaise, elevated 
liver enzyme levels, renal failure and bone marrow suppression (Greinwald et al. 1999). 
Flashlamp-Pumped Pulsed Dye Laser treatment has been found to be somewhat limited 
for haemangiomas, as the lasers used can only penetrate the upper dermis and are 
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unable to prevent proliferation o f the deep component o f haemangiomas (Poetke et al. 
2000). The chemotherapeutic drug vincristine is another therapeutic option for 
complicated haemangiomas that have not responded to corticosteroid treatment. The 
main dose l imit ing effect o f vincristine is neurotoxicity (Chan et al. 2005), but other 
potential side effects include fever, headache, gastrointestinal upset and alopecia. 
More recently, the use o f topical imiquimod cream, which works as an immune-
response modifier affecting both the innate and acquired immune system, was shown to 
be successfial in controlling superficial infantile haemangiomas, but had minimal effect 
on deeper subcutaneous haemangiomas (Ho et al. 2007). Surgical resection is typically 
considered when haemangiomas are not responding to other medical treatment (Hussain 
et al. 2008). Lesions which are prone to bleeding and ulceration, or are function-
impairing are often considered for removed surgically. Surgery can also be used for 
cosmetic improvement after involution has occurred, as the lesions often leave 
cosmetically significant changes including discolourafion, redundant skin, fibrofatty 
tissue and scarring (Chan et al. 2005). 
More recently, a number o f clinical trials have shown the effectiveness o f intralesional 
bleomycin injection for the treatment o f haemangiomas (Sarihan et al., 1997; 
Kullendorff, 1997; Mui r et al., 2004; Omidvari et al., 2005; Pienaar et al., 2006), often 
eliminating the need for surgery or systemic treatment regimens in 80% o f cases (Oak et 
al., 2006). These studies are as yet not randomised controlled trials. 
1.4 Keloid Scars 
1.4.1 General 
Keloid is an abnormal healing response, characterised by excessive accumulation o f 
extracellular matrix and by overabundant collagen formation (Singer et al. 1999). At 
present, the mechanism that causes these phenomena is not fially understood. Keloid 
scars can occur after a variety o f cutaneous injuries, including surgery, bums dermal 
trauma and acne. In contrast to hypertrophic scars, keloids do not regress with time, are 
diff icul t to revise surgically and often exceed the boundaries o f the initial injury 
(Ehrlich et al. 1994). Keloids have been linked clinically to the cytokine transforming 
growth factor-13 or TGF-13 (Lee at al. 1999). TGF-/3 is essential for wound healing; 
however excessive production o f TGF-B can result in increased deposition o f scar tissue 
and fibrosis. Platelet derived growth factor (PDGF) is also known to regulate cell 
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proliferation and differentiation. TGF-6 was shown to upregulate the expression of 
PDGF receptors in keloid fibroblasts, but not in normal skin fibroblasts (Messadi et al. 
1998). 
1.4.2 Treatment of Keloid scars 
There is no fiindamental treatment for keloid scars. Current treatment is by palliative 
modalities such as pressure (Brent 1978), intralesional injections o f corticosteroids ( K i i l 
1977), topically applied silicones or gel sheets or surgical excision (Cosman et al. 
1972). Surgical excision is usually only temporarily beneficial, due to the high 
recurrence rate o f keloid. More recently the use o f bleomycin for the treatment o f these 
scars has proved successful (Bodokh et al., 2006; Espana et al., 2001; Saray et al., 2005; 
Aggarwal et al., 2008). However these studies were not randomised controlled trials. 
1.5 Aims of the thesis. 
Bleomycin has been used successfijlly in the treatment o f haemangioma, keloid and 
vascular malformation, however the mode o f action o f this chemotherapeutic drug on 
these non-malignant dysplasias is not well understood. One approach to begin to 
understand these modes o f action is to derive cell lines from these dysplasias so as to 
allow study in vitro. Given that the primary means o f action on neoplastic cell types is 
through apoptosis and cell cycle arrest, these cell lines should be investigated for their 
sensitivity to bleomycin. 
Work described in this thesis reports the isolation o f primary cell lines from infantile 
haemangioma, vascular malformation and keloid. The effect o f bleomycin on these and 
control cell lines was investigated in a staged manner, initially assessing dose 
responsiveness for a range o f cell types in vitro, and subsequently focussing on potential 
mechanisms of action. 
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2 Materials and Methods 
2.1 Materials 
Unless otherwise specified, all materials were sourced from Sigma-Aldrich (Dorset, 
UK) , all procedures were carried out at room temperature and all percentages are 
expressed as volume/volume (v/v). A list o f buffers employed, and their constituent 
parts are listed in Appendix 1. Manufacturers of equipment and materials employed can 
be found in Appendix 2. 
2.2 Tissue culture 
This study has used two sources of cells; primary cells established from tissue specimens 
of haemangiomas, keloids, venous malformations and lymphatic malformations (2.3.1) 
in addition to established cell lines. A l l culture materials were either purchased as 
aseptic stock or sterilised by autoclaving, unless otherwise indicated. 
2.3 Primary cells established from human tissue samples 
Tissue specimens were obtained from the James Cook University Hospital, 
Middlesbrough in accordance with the Human Tissue act. Full details o f ethical approval 
can be found in appendix 3. 
2.3.1 Tissue preparation 
Tissue specimens were taken immediately after resection and placed on ice. The samples 
were then washed twice in double strength antibiotic medium (minimum essential media 
(MEM) containing 20% (v/v) foetal bovine serum (Harlan), 2mM L-glutamine, 
100|ig/ml gentamycin solution and 500|ig/ml amphotericin B). The tissue was cut into 
small pieces, typically Icm^ in size and stored at 4°C for 2-4 hours in a sufficient 
volume of double strength antibiotic media to cover the sample (typically 25ml). This 
latter step was performed to reduce the risk of the bacterial and/or fiingal contamination 
of the tissue samples infecting the subsequent cultures. The samples were then placed in 
explant culture, taken for collagenase digestion or snap frozen for storage. 
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2.3.2 Explant culture 
A portion of each of the tissue samples were removed from the double strength 
antibiotic media and cut into approximately Imm^ sized pieces, using a scalpel or 
surgical scissors. The tissue pieces were then placed on the growing surface o f 35mm x 
10mm cell culture dishes (Nunc) and left in the absence o f media for 5 minutes to allow 
the tissue to adhere to the surface o f the dish. One millilitre o f growth medium 
appropriate for the tissue under study (see Appendix 1) was then added and the samples 
cultured in a humidified incubator (SHEL L A B ) at 37°C and 5% CO2, for a period o f 7-
28 days, a period of time dictated by the rate o f cellular outgrowth from the explant 
during culture. The growth media was replaced every 7 days. When the cells which had 
grown out o f the explants were ready to be passaged, the tissue segments were 
physically removed from the surface o f the dishes using sterile forceps. The remaining 
adherent cells growing on the surface of the dish were then washed twice with sterile 
phosphate buffered saline (PBS - lOX +calcium +magnesium) (Gibco) and detached by 
incubation for approximately 5 minutes with 1ml Trypsin-ethylenediamine tetra acetic 
acid (Trypsin-EDTA). 1ml o f growth media was then added to neutralise the trypsin 
before centrifugation at 300 x g for 5 minutes. The cells were resuspended in 5ml 
growth media and transferred to a 25cm^ cell culture flask (Nunc) and cultured in a 
humidified incubator at 37°C and 5% CO2. After passage 2 cells were transferred to a 
75cm^ flask and these cell lines were cultured up to passage 11 to allow for subsequent 
experiments. 
2.3.3 Collagenase digestion 
Tissue specimens were minced with surgical scissors and subsequently digested with 
approximately 20ml of filter-sterilised 0 .1% (w/v) type 1 collagenase (Worthington) in 
M E M containing 2% FBS at 37°C for 1 hour. The tissue was homogenised with a pesde 
and mortar and filtered through 100-|jm cell strainers (BD Falcon™) to obtain a cell 
suspension. The cells were centrifliged for 5 minutes at 300 x g. The pellet was gently 
resuspended in 2ml o f hypotonic ammonium chloride solution, and incubated for 10 
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minutes to lyse any residual erythrocytes. This was pelleted once more at 300 x g and 
resuspended in 5ml o f growth media appropriate for the tissue type under study (see 
appendix 1). The cell suspension was then transferred into 25cm^ tissue culture flasks 
(Nunc) and incubated at 37°C and 5% CO2. 
2.4 Established cell lines 
2.4.1 Passaging cells 
Cells were passaged when they reached 70-80% confluency. The growing surface o f the 
flask was washed twice with lOmls o f PBS before adding 2-4mls o f trypsin-EDTA. 
Cells were then incubated at room temperature (HUVEC) or 37°C (all other lines) for 5 
minutes until the cells detached from the surface o f the flask. Five millilitres o f the 
appropriate growth media was then added to the flask to neutralise the trypsin. The 
resulting cell suspension was then centrifiiged for 5 minutes at 300 x g. The cell pellet 
was resuspended in 2mls o f growth medium and then split equally between two 75cm^ 
flasks. A l l cells were grown in humidified SHEL L A B incubators at 37°C and 5% CO2. 
2.4.2 Culture of HUVEC cell line 
Normal Human Umbilical Vein Endothelial Cells (HUVEC) were purchased from 
Promocell, Heidelberg, Germany. The cells were grown in Endothelial Cell Growth 
Medium M V (Promocell), the ingredients o f which can be found in appendix 1. 
2.4.3 Culture of HMEC-1 cell line 
HMEC-1 cell line was kindly supplied by Dr. Noel Carter (Senior Lecturer, Faculty of 
Applied Science, University o f Sunderland). This cell line is an immortalised human 
microvascular endothelial cell line that retains the morphologic, phenotypic, and 
functional characteristics of normal human microvascular endothelial cells (Ades et al. 
1992). Cells were grown in MCDB-131 growth medium supplemented with 10% FBS, 
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lOng/ml human epidermal growth factor (EGF), l^ig/ml hydrocortisone, and 50p,g/ml 
gentamycin and 250^lg/ml amphotericin B. 
2.4.4 Culture of Human Foreskin Fibroblasts 
Cultured primary human foreskin fibroblasts were kindly supplied by Dr Rebecca Hi l l 
(Durham University). The cells were grown in M E M supplemented with 10% (v/v) FBS, 
2mM L-glutamine, 50^g/ml gentamycin and 250ng/ml amphotericin B. 
2.4.5 Freezing cells 
Cells in culture were detached using trypsin-EDTA (as described in 2.4.1) and combined 
with an equal amount of growth medium before centrifiagation at 300 x g for 5 minutes. 
The cell pellet was then resuspended in 2ml o f freezing solution containing 70% growth 
medium, 20% FBS and 10% dimethylsulphoxide (DMSO), transferred to fi-eezing vials 
(Nunc). The vials were then slowly frozen in a -80°C freezer and stored in liquid 
nitrogen. 
2.4.6 Thawing of frozen cells 
Vials of frozen cells were thawed quickly in a 37°C waterbath. Defrosted cells were 
added to 10ml o f growth medium and centrifiiged at 300 x g for 5 minutes and the pellet 
resuspended in 1ml of growth medium. Cells were then transferred to a 25cm^ or 75cm^ 
tissue culture flask and grown as described earlier. 
2.4.7 Counting cells using a Haemocytometer 
To ensure the haemocytometer was clean, it was cleaned with 70% ethanol before each 
use and the edge of the haemocytometer surface was then moistened to ensure the cover 
slip was completely affixed. The cells were trypsinised as described (2.4.1). The cell 
suspension was the aspirated several fimes using a sterile 1ml pipette to thoroughly mix 
the cells before removing 20|il of cell suspension. 10|il was added to either side of the 
dual haemocytometer (Hausser Scientific) and counted using a hand tally counter and 
the mean cell number was used. The haemocytometer has 2 grids for counting cells, 
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which measure Imm'^ in area x 0.1mm in depth, with a total volume of 0.1 mm^ = 10'*/ml. 
A l l cells were counted under a light microscope at xlO magnification. 
2.5 Apoptosis assays 
Adherent cells were trypsinised and counted as described in parts 2.4.1 and.2.4.7. For 
bleomycin dose response experiments, 6 well cell culture dishes were used (Greiner). 1 x 
10'* cells were plated out per well with 2ml o f growth media. The cell plates were then 
incubated for 48 hours, before the addition o f bleomycin. This method was used for all 
apoptotic assays. 
2.5.1 Bleomycin treatment 
Bleomycin sulphate fi-om Bleo-kyowa, (Slough, UK) is used in the clinic to treat 
haemangioma. The drug comes in vials containing 15,000IU of lyophilised powder. Five 
millilitres o f sterile PBS was added to a single vial of bleomycin, to make a 3000U/ml 
stock. The stock solution is stable for 3 months stored at 4°C. Using the stock solution, a 
range of concentrations lmU-50,000mU/ml was made up in the relevant growth media. 
After 48 hours incubation with growth media, the media was removed and replaced with 
growth media containing varying concentration o f bleomycin. Control samples were also 
set up by replacing the growth media with fresh growth media containing no bleomycin. 
Cells were then incubated at 37°C for 5 hours, 24 hours and 48 hours, after which the 
samples were harvested by trypsinisation, and prepared for nmning on the flow 
cytometer as described in (2.6.2). 
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2.6 Principles of flow cytometry 
Flow cytometry can measure and analyse multiple physical characteristics of single 
cells. The properties measured can include size, granularity or internal complexity, and 
relative fluorescence intensity. The flow cytometer used in this study was a Becton 
Dickenson FACSCalibur, which can measure five parameters, forward light scatter 
(FSC), side light scatter (SSC) and three fluorescence parameters, F L l (filter: 530/30), 
FL2 (filter: 585/42) and FL3 (filter: >670nm). 
A flow cytometer consists o f three main systems: fluidics, optics, and electronics 
(Ochatt., 2006). The fluidics system is responsible for transporting the cell sample 
through a narrow stream of fluid, allowing the cells to pass individually through a laser 
beam. The optics system consists o f lasers to illuminate the cells in the sample stream. 
When a laser interacts with the cells, it can be scattered by reflection or refraction, which 
is indicative of the cells size and granularity, or it can be converted to a new wavelength 
by cell associated fluorochrome (fluorescence). The optical filters then direct the 
resulting light signals to the appropriate detectors. The electronics system converts the 
detected light signals into electronic signals (voltages) by photodetectors. The voltage 
pulse is assigned a digital value by the Analog-to-Digital Converter (ADC). Once the 
ADC has converted these voltage pulses to channel numbers, the data is stored and 
processed by the computer (Robinson, 2006). This results in detailed quantitative 
information about each cell analysed. 
In this study apoptosis and cell death were examined using 3 methods: staining fixed 
cells with propidium iodide (PI) to look at the integrity o f nuclear DNA (2.6.1), DNA 
damage using the terminal deoxynucleotidyl transferase dUTP nick end labelling 
(TUNEL) assay (2.7) and detection of apoptosis by intracellular staining using a cleaved 
caspase-3 conjugated antibody (2.8). 
2.6.1 Investigation of cell cycle and apoptosis using flow cytometry 
One method that can be used to quantify apoptosis by flow cytometry is the use of 
propidium iodide (PI). The PI intercalates between bases o f double stranded DNA and 
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produces a highly fluorescent adduct. PI is excited by UV or blue light to emit red 
fluorescence (Ormerod, 2000). The flow cytometer can then analyse the cells based on 
the quantity o f DNA in each cell. Cells in gap 1 phase ( G l ) have one complement of 
DNA. In this phase, the cell is synthesising proteins required for replication. Cells then 
progress to the synthesis phase (S phase) where new DNA is being synthesised. Once 
the DNA content in the cell has doubled, the cell has reached gap 2 phase (G2) where 
the cell is synthesising proteins required for mitosis. Therefore cells in G l have one 
complement of DNA, and cells in G2 have double the content of DNA than cells in G l . 
Cells in S phase have DNA content between that of G l and G2. Apoptosis is 
characterised by loss of cell volume, clumping o f chromatin and nuclear fragmentation 
into apoptotic bodies, so the DNA complement is <1 (Nicoletti et al. 1991) and so 
apoptotic cells are identified as the sub-Gl fraction o f the cell cycle. 
Since PI can also bind to double stranded ribonucleic acid (RNA), it is necessary to treat 
the cells with RNAse to degrade the RNA that may bind PI, to optimise DNA resolution. 
As this method relies on analysing individual cells, cell clumping was avoided by 
passing cells through a syringe and needle before running the samples through the flow 
cytometer. A clump of two cells in G l would have the same DNA content as one cell in 
G2; however these clumps or doublets can be distinguished by size on the forward 
scatter versus side scatter plot and can be gated out, so they are not included in the cell 
cycle measurements. 
2.6.2 Sample preparation: PI staining fixed cells 
To investigate cell cycle distribution and apoptosis, both treated and untreated cells were 
harvested at 5 hours, 24 hours and 48 hours. As the cultures in these experiments are of 
adherent cells, cells in the supernatant of the samples have a higher probability o f being 
apoptotic than do the adherent cells, and therefore the cells in the supernatant were also 
harvested prior to trypsinisation and spun down with the trypsinised adherent cell layer. 
The cells were spun at 1500 rpm for 5 minutes to remove trypsin and media. The cell 
pellet was resuspended in 600^1 of ice cold PBS, then fixed with the addition o f 1400^1 
ice cold 100% ethanol. Fixed samples were stored at 4°C. Prior to running on the flow 
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cytometer, the cells were centrifuged at 1500 rpm for 5 minutes to remove the ethanol 
and PBS. The cell pellets were resuspended in 400|il of ice cold PBS. 50|il of 40|ig/ml 
PI and O.lmg/ml RNAse A were added to each sample and incubated for 30 minutes at 
37°C. 
2.6.3 Flow cytometer settings 
To acquire the appropriate settings for analysis o f the test samples, a control sample was 
first run through the flow cytometer. Dot plots showing the side scatter (SSC) versus 
forward scatter (FSC) and FL2-W versus FL2-A and FL2-height histogram were used to 
assess the data collected. The G l peak o f the cell cycle should be at approximately 200 
FL2-H (one complement of DNA) and the G2 peak at 400 FL2-height (double DNA 
content of G l ) . For each test sample 10,000 events were recorded and each experiment 
was performed in triplicate. 
2.6.4 Data analysis 
The data was analysed using W i n M D l 2.8 software (TSRI flow cytometry core facility. 
La Jolla, CA). To ensure only single cells were analysed, the cells were gated using the 
FL2-W versus FL2-A dot plot. The gated data was plotted as an FL2-histogram and to 
determine the percentage of cells in G l , G2, S and sub-Gl, the cells were defined by 
their individual peaks as M l , M2, M3 and M4. Cells undergoing apoptosis were found 
in the sub-Gl portion o f the histogram (M4). 
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2.7 Detection of DNA fragmentation by flow cytometry using APO-
DIRECT" Kit 
2.7.1 Principles of the TUNEL assay 
The APO-DIRECT^M i^jt is based on the TUNEL assay (Li et al., 1995) and is a single 
step assay for labelling DNA breaks and total cellular DNA to detect apoptotic cells by 
flow cytometry. One feature of apoptosis that can be easily measured is the break-up of 
the genomic DNA by cellular nucleases. Apoptotic cells contain a large number of DNA 
fragments, which result in a nimiber of 3'-hydroxyl ends o f DNA. This kit uses this 
property to identify apoptotic cells by labelling the DNA breaks with a fluorescein 
isothyocyanate (FITC) labelled deoxyuridine triphosphate nucleotides (dUTP). Non-
apoptotic cells do not incorporate significant amounts o f the FITC-dUTP due to the lack 
of exposed 3'-hydroxyl DNA ends and therefore be identified as a negadvely stained 
population. This kit also contains PI and RNAse A solution for counter staining the total 
DNA content of each cell. 
2.7.2 Fixation protocol 
The test cells were harvested as described earlier. The cells were then centrifiiged for 5 
minutes at 300 x g and the supernatant discarded. The cells were then resuspended in 1% 
paraformaldehyde in PBS (pH 7.4). The cells were then placed on ice for 30-60 minutes. 
The cells were then centrifiiged for 5 minutes and 300 x g and resuspended in PBS. This 
wash step was repeated with PBS and the pellet resuspended in 70% ethanol. The cells 
were then stored at -20°C until all test samples were ready to be analysed by flow 
cytometry. 
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2.7.3 Staining protocol 
The following procedure describes the method for measuring apoptosis in the positive 
and negative controls that are provided with the APO-DIRECT™ kit. The same 
procedure was followed for the bleomycin treated samples. 
The cells of the positive and negative controls were resuspended by swirling the vials. 
1 ml aliquots of the positive and negative controls were removed and placed into separate 
1.5ml epindorf tubes. The cells were centrifuged for 5 minutes at 300 x g and the 70% 
(v/v) ethanol removed by aspiration. Each cell sample was resuspended in 1ml wash 
buffer and spun for 5 minutes and 300 x g. The centrifugation step was repeated and 
supernatant removed by aspiration. Each sample was then resuspended in 50]i\ of 
staining solution and incubated at 37°C for 60 minutes. At the end of the incubation 
time, 1ml o f wash buffer was added to each of the cell samples and the samples were 
centrifuged at 300 x g for 5 minutes. The rinse step was repeated with 1ml of rinse 
buffer and the supernatant was removed by aspiration. The cell pellet was then 
resuspended in 500|il of PI/RNAse staining buffer and then incubated for 30 minutes at 
room temperature in the dark. The cells were then analysed in the Pl/RNAse solution 
within 3 hours o f staining. Each experiment was performed in triplicate. 
2.7.4 Analysis of samples by flow cytometry 
The samples were measured on a Becton Dickenson FACSCalibur. The positive and 
negative controls provided with the kit were analysed first. A dual parameter dot plot 
and single parameter histogram were used to show the data. To display DNA doublet 
discrimination, FL2-width was plotted on the X-axis versus FL2-area on the Y-axis. 
From this display, only single cells are gated. The gated data was then plotted onto a 
single parameter histogram, showing FL-1 (FITC-dUTP), to identify the percentage of 
cells positive for DNA strand breaks. 
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2.8 Detection of Apoptosis by Intracellular Immunostaining for Cleaved 
Caspase-3 
2.8.1 Background 
Caspase-3 (CPP32, apoptain, Y A M A , SCA-1) belongs to a set o f mediators implicated 
in apoptosis known as aspartate-specific cysteinyl proteases or caspases. Caspase-3 has 
been identified as a key mediator in mammalian cell apoptosis, as it is partially or totally 
responsible for the proteolytic cleavage of many key proteins (Nicholson et al. 1997; 
Cohen, 1997; Woo et al. 1998). The processed form o f caspase-3 consists of a small 
(12kD) and large (17kD) subunits, which associate to form an active enzyme. Cleaved 
caspase-3 antibody (Alexa Fluor 488 Conjugate) works by detecting endogenous levels 
of the large fragment of activated caspase-3 resulting from cleavage adjacent to aspartic 
acid 175. 
2.8.2 Sample preparation 
Cells were plated out as previously described (2.5) and treated with bleomycin (2.5.1). 
2.8.3 Fixation protocol 
Test cells were harvested by trypsinisation as previously described. The cells were 
centrifiiged for 5 minutes at 300g and resuspended in 300|J1 o f ice cold PBS. 700|LI1 o f 
ice cold ethanol was added to each tube and the samples placed on ice for 60 minutes or 
left overnight at -20°C. 
2.8.4 Reagent preparation 
To make incubation buffer, 0.5g of bovine serum albumin (BSA) was dissolved in 
100ml of PBS. 
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2.8.5 Staining protocol 
2ml of incubation buffer was added to each o f the samples and centrifuged for 5 minutes 
at 300g. The cell pellet was resuspended in 90)il o f incubation buffer. The cells were 
incubated for 10 minutes at room temperature in incubation buffer, before the addition 
of 10|il of the conjugated antibody. The samples were incubated in the dark at room 
temperature for 1 hour. Cells were rinsed and resuspended in 300\i\ o f PBS. 
2.8.6 Analysis by flow cytometry 
The samples were measured on a Becton Dickenson FACSCalibur. Control samples 
were analysed first to acquire the appropriate settings. Dual parameter dot plots showing 
side scatter on the Y axis, versus FL-1 (alexa-fluor 488) on the X axis were plotted to 
display the data. The data obtained from the flow cytometer was analysed using 
W i n M D l 2.8. The data was plotted onto a dual parameter dot plot (as before) and gated 
to determine the percentage of cells which were positive for cleaved caspase-3 antibody. 
2.9 Statistical analysis 
A l l data presented are representative of the mean of 3 independent experiments ± SD. A 
Student's unpaired two-way t-test was used to compare data between control and test 
samples. In cases where both time and dose were analysed, these dual variables were 
also subjected to 2-way A N O V A . Where statistical significance is indicated, this was 
achieved using both tests unless otherwise indicated. Graphs and statistical analysis were 
carried out in Excel and SPSS 14.0. 
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3 Results 
3.1 Explant Cultures 
In order to examine the effects o f bleomycin in vitro, explant cultures were used to 
derive primary cell lines. Tissue was obtained from surgically excised tissue (that 
would have otherwise been discarded) from untreated haemangiomas, keloid scars and 
venous malformations over a period o f 10 months and explants cultured for up to four 
weeks. Single cell cultures were produced from the tissue using collagenase digesfion; 
however no cell lines developed using this technique. From the explant cultures, five 
cell lines were established (2 haemangioma, 2 keloid, 1 venous malformation) fol lowing 
protocols described in section (2.3.2). After approximately 3-4 weeks, each cell line had 
grown to confluence in a 35mm x 10mm cell culture dish, at which point the cells were 
trypsinised and transferred to 25cm^ cell culture flasks. 
The keloid derived cells in culture appeared fibroblastic and homogeneous in size and 
morphology fol lowing the first passage from explant culture. The fibroblast-like 
morphology was maintained after cell passages and throughout the culture period. 
Inifially, the cell outgrowth from the haemangioma explants appeared to be 
heterogeneous, but this soon disappeared with all cells appearing to be o f a similar size 
and morphology (figure 3.1). The passage frequency for these cell lines ranged between 
4-7 days. Three o f the cell lines derived from the tissue samples (1 haemangioma, 1 
keloid, 1 venous malformafion) were used for the following experiments along with 
established cell lines, HUVEC, HMEC-1 and foreskin fibroblasts. 
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Figure 3.1 Subconfluent monolayer of primary fibroblast-like cells derived from (a) 
proliferative haemangioma and (b) keloid. Cells magnified using phase contrast microscopy (10 x 
objective). 
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3.2 Flow cytometry results 
3.2.1 Investigation of cell cycle and apoptosis using flow cytometry 
Flow cytometry experiments were performed using the method described in section 2.6. 
All cells were cultured with increasing doses of bleomycin (l-10,000mU/ml) and 
assayed at 5, 24 and 48 hours. Apoptosis was measured by propidium iodide (PI) 
staining to determine the percentage of cells with subdipliod DNA content. 
3.2.2 Cell cycle analysis 
A representative cell cycle dot plot and histogram for the foreskin fibroblasts are shown 
on figure 3.2(a&b) to illustrate how the flow cytometry data was obtained. 
The G1:S ratio for each cell line before and after treatment with a range of 
concentrations of bleomycin was compared to that of their untreated controls. Gl arrest 
was identified by an increase in the proportion of cells in Gl phase and a decrease in the 
proportion of cells in S phase. The G1:S ratio versus time for each cell line at various 
doses of bleomycin is shown on figure 3.3(a-d). With the exception of HMEC-1, all cell 
lines evaluated appeared to show a bleomycin induced increase in G1:S ratio (Gl arrest) 
at a dose of lOOmU/ml after 48 hours, this was statistically significant in the case of 
foreskin fibroblast, HUVEC and haemangioma derived cells (figure 3.4.a). 
Foreskin fibroblasts underwent Gl arrest, with the mean G1;S phase ratio for 
increasing fi-om 6.13 ± 0.43 in the control, to 9.73 ± 0.58 in the lOOmU/ml sample 48 
hours post treatment with bleomycin (figure 3.3(a)). 
The keloid derived cell line was also shown to undergo Gl arrest in response to 
treatment with bleomycin at a concentration of lOOmU/ml. The G1:S phase ratio 
increased fi-om 10.76 ± 1.38 in the control, to 17.10 ± 4.13 in the lOOmU/ml bleomycin 
treated sample 48 hours post treatment (figure 3.3(b)). 
HUVEC cells underwent Gl arrest, this was observed at a concentrafion of lOOmU/ml 
at both 24 and 48 hours post treatment with lOOmU/ml bleomycin. The initial mean 
G1:S ratio for the HUVEC control sample was 4.52 ± 0.46, which increased to 19.10 ± 
2.32; 48 hours post treatment with lOOmU/ml bleomycin (figure 3.3(c)). 
Haemangioma derived cells also underwent Gl arrest in response to treatment with 
bleomycin. This was observed at a concentration of lOOmU/ml at both 24 and 48 hours 
post treatment (figure 3.3(d)). The initial mean Gl.S ratio for the haemangioma control 
sample was 5.57 ± 0.58, increasing to 16.49 ± 6.59, 48 hours post treatment. 
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The HMEC-1 cells failed to undergo a Gl arrest in response to Bleomycin treatment 
(data not shown). The mean Gl :S phase ratio decreased from 2.61 ± 0.11 in the control 
sample, to 2.13 ± 0.13, 48 hours post treatment with lOOmU/ml bleomycin. The 
proportion of cells in G2 increased in the 48 hour HMEC-1 sample treated with 
lOOmU/ml bleomycin (the proportion of cells in Gl decreased). This suggests that the 
HMEC-1 cell line undergo a G2 arrest as opposed to a Gl arrest after treatment with 
bleomycin. 
The increase in Gl.S ratio induced by bleomycin is shown on figure 3.4(b). Compared 
with foreskin fibroblasts, HUVEC, haemangioma derived cells and keloid derived cells 
all showed a greater increase in G1:S ratio. This was statistically significant in the case 
of HUVEC and keloid ( P= < 0.01; P = < 0.05 respecfively). 
24 
Results 
P 
S-phase 
Sub-Gl 
FL2-Width 
c 
o 
U 
FL2-height 
1023 
Figure 3.2 Representative width/area dot plot and FL2 histogram analysis of foreskin 
fibroblasts, (a) shows the gate (in red) used to identify single cells, following the method of 
Mullen, 2004. (b) The cells gated data as in previous figure (a) were plotted as an FL2 
histogram. To determine the percentage of cells in G l , G2, S and sub-Gl, the cells were 
defined by their individual peaks as M l , M2, M3 and M4 respectively. 
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Figure 3.3(a&b) Effects of bleomycin dose and time of exposure on G1:S ratio of foreskin 
fibroblasts (a) and keloid (b). A significant increase in G1:S ratio was observed at a 
concentration of lOOmU/ml after 48 hours incubation with the foreskin fibroblasts. Variance 
between samples meant that difference observed with the keloid derived cells was not 
significant Results are presented as the Mean ± SD of 3 independent experiments. *• = P < 0.01 
for T-test (NS for 2-way ANOVA) 
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Figure 3.3(c&d) Effects of bleomycin dose and time of exposure on G1:S ratio of H U V E C 
(c) and haemangioma (d). A significant increase in Gl :S ratio was observed at a concentration 
of lOOmU/ml after 24 and 48 hours incubation with the HUVEC and haemangioma derived 
cells. Results are presented as the Mean ± SD of 3 independent experiments. * = P < 0.05, •* = 
P<0.01 
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Figure 3.4(a): Cell cycle analysis of cell lines in the presence or absence of bleomycin. 
Results are expressed as G1:S phase ratios for the 5 cell lines 48hours post treatment with 
lOOmU/ml bleomycin. With the exception of HMEC-1, all cell lines showed a bleomycin 
induced increase in G1:S ratio (b) Bleomycin induced increase of G1:S ratio. The data 
from (a) is expressed as absolute increase in Gl :S ratio. Compared with foreskin fibroblasts, 
the other three cell lines showed a greater increase in G1:S ratio. This was statistically 
significant in the case of keloid and HUVEC. * = P< 0.05; ** = P< 0.01. Results are 
presented as the mean ± S.D. 
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3.2.3 Sub-Gl analysis 
Bleomycin dose response at 24 hours and 48 hours for all cell lines is shown on figure 
3.5(a) and 3.5(b) respectively. Cells were fixed and permeabilised then incubated with 
fluorochrome (PI) as described in 2.6.2. Apoptotic cells were identified as sub-Gl 
population. The bleomycin induced increase in sub-Gl percentage was calculated as 
(sub-Gl % in the presence of bleomycin - sub-Gl % in the absence of the drug). 
The results demonstrate that bleomycin-induced DNA damage was both concentration 
and time dependent for all cells; however differences in response to bleomycin was 
observed between cell lines. 
At lower doses of 1, 10 and 1 OOmU/ml bleomycin, the percentage of cells in the sub G1 
fi-action did not increase significantly in the foreskin fibroblast at both 24 and 48 hours. 
At the higher dose of 1 OOOmU/ml, no significant difference was observed after 24 hours 
incubation; however after 48 hours a significant increase in sub-Gl % was observed 
(Table 1). 
No increase in sub-Gl % was observed at 1, 10, 100 and lOOOmU/ml bleomycin in the 
keloid derived cells after 24 hours incubation (Table 2). At the higher dose of 
10,000mU/ml, an increase in sub-Gl % was observed, however variance between 
samples meant that this difference was not statistically significant (P> 0.05). After 48 
hours incubation, an increase in sub-Gl % was observed at 1, 100, 1000 and 
10,000mU/ml; this increase was statistically significant in the case of 10,000mU/ml 
treated sample (P< 0.05). 
HUVEC and venous malformation derived cells showed a statistically significant 
increase in sub-Gl % at 1000 and 10,000mU/ml at both 24 and 48 hours incubation (P< 
0.01). The increase observed at lower doses for these to cell lines were not statistically 
significant (Tables 3&6). 
At lower doses of 1, 10 and lOOmU/ml bleomycin, the sub-Gl % of HMEC-l cells did 
not increase significantly (Table 4). At the higher dose of lOOOmU/ml, 24 hours 
incubation did not cause a significant increase in sub-Gl%; however after 48 hours 
incubation at this dose, the increase in the percentage of cells in sub-Gl was statisfically 
significant (P< 0.01). At the highest dose of 10,000mU/ml, a statistically significant 
increase was observed at both 24 and 48 hours (P< 0.05, P<0.01 respectively). 
None of the increases observed in sub-Gl % in the haemangioma derived cells were 
found to be statisfically significant, due to considerable variance between samples 
(Table 5). 
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At the higher dose of 10,000mU/ml, all cell lines showed an increase in sub-Gl 
percentage at both 24 and 48 hours. After 48 hours incubation with lOOOmU/ml or 
10,000mU/ml bleomycin, HUVEC apoptosis did not increase significantly from the 
degree of apoptosis that was observed at 24 hours incubation at these doses. In contrast, 
keloid and venous malformation derived cells, HMEC-1 cells, and foreskin fibroblasts 
displayed an increase in apoptosis with longer exposure at lOOOmU/ml and 
10,000mU/ml (see figure 3.6). An increase in the proportion of cells in sub-Gl was 
observed in the haemangioma derived cell line after longer incubation with lOOOmU/ml 
and 10,000mU/ml of bleomycin; however variance between samples meant that this 
observation was not statistically significant. This data suggests the effect of bleomycin 
on HUVEC cells appears to be maximal within 24 hours. 
The detecfion of a sub-Gl DNA peak is a specific marker of apoptosis; cell death by 
necrosis does not induce any sub-Gl peak (Nicoletti et al. 1991). However, in addition 
to apoptotic cells, the sub-Gl peak can also represent mechanically damaged cells and 
isolated apoptotic bodies, resulting in an over-estimation of apoptotic cell percentage. 
Therefore it was necessary to confirm that the observed increase in sub-Gl cells was 
indeed due to apoptosis. Apoptosis is characterised by activation of nucleases which 
produce a large number of DNA strand breaks (Nicoletti et al. 1991). Detecfion of these 
breaks was performed using the APO-DIRECT™ kit based on the Terminal 
deoxynucleotidyl fransferase dUTP nick end labelling (TUNEL) assay. 
26 
Results 
25.00 
20.00 
O 
X I 3 
CO 
c 
16.00 
10.00 
O 
5.00 
0.00 
(a) 
24 hours 
-Keloid 
- Proliferatve Haemangioma 
HMEC-1 
- Foresicin Fibroblast 
-HUVEC 
-Venous Malfomiation 
10 100 1000 
Bleomycin Concentration (mU/ml) 
10000 
30.00 
20.00 
0} 10 00 
48 hours 
-Keloid 
- Proliferative Haemangioma 
HMEC-1 
- Foreskin Fibroblasts 
-HUVEC 
-Venous malfomiation 
10 100 1000 
Bleomycin Concentration (mU/ml) 
10000 
Figure 3.5 Effect of bleomycin treatment on the percentage of cells in sub-Gl fraction. Cells were 
cultured in the presence or absence of different bleomycin concentrations for 24 hours (a) or 48 hours 
(b). Results are expressed as (% sub-Gl in the presence of bleomycin - % sub-Gl in the absence of the 
drug). Data displayed are the means of 3 independent experiments. SD is not shown in this figure for 
reasons of clarity. 
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Table 1: Mean ± SD of bleomycin induced increase in sub-Gl % in foreskin fibroblasts 
Bleomycin (mU/ml) 
24 hours 
Increase in sub-Gl %^ 
48 hours 
ImU/ml 
10mU/ml 
lOOmU/ml 
lOOOmU/ml 
lOOOOmU/ml 
0.36 ±0.81 
0.17 ±0.60 
0.20 ± 0.48 
0.41 ±0.14 
6.83 ± 2.74* 
0.11 ±0.18 
5.31 ± 2.22* 
1 1 . 6 8 ± 4 . i r 
Data from three independent experiments 
- = No increase observed when compared to untreated control 
* = P< 0.05, ** = P< 0.01 
Table 2: Mean ± SD of bleomycin induced increase in sub-G1% in keloid derived cells 
Bleomycin (mU/ml) 
24 hours 
Increase in sub-Gl % ^ 
48 hours 
ImU/ml 
10mU/ml 
lOOmU/ml 
lOOOmU/ml 
lOOOOmU/ml 8.15 ± 1.06 
0.14 + 0.22 
0.33 + 0.46 
4.62 ± 3.92 
18.21 ±4.85* 
^Data from three independent experiments 
- = No increase observed when compared to untreated control 
* = P< 0.05. 
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Table 3: Mean ± SD of bleomycin induced increase in sub-G1% in HUVEC 
Bleomycin (mU/ml) 
24 hours 
Increase in sub-G1 % 
48 hours 
ImU/ml 
10mU/ml 
lOOmU/ml 
lOOOmU/ml 
10000mU/ml 
0.10 ± 0.83 
0.67 ± 0.92 
1.09 ±0.99 
6.90 ± 1.04** 
19.08 ± 1.16** 
0.11 ±0.21 
5.07 ± 0.93** 
20.71 ±1.94* 
^Data from three independent experiments 
- = No increase observed when compared to untreated control 
** = P< 0.01 
Table 4: Mean ± SD of bleomycin induced increase in sub-Gl % in HMEC-1 
Bleomycin (mU/ml) 
24 hours 
Increase in sub-G1 %^ 
48 hours 
ImU/ml 
lOmU/ml 
lOOmU/ml 
lOOOmU/ml 
lOOOOmU/ml 
2.58 ± 1.20 
8.80 ± 4.28 
2.28 ± 7.45 
0.27 ± 2.43 
2.82 ± 2.60 
12.32 ±2.36** 
24.46 ± 1.62** 
^Data from three independent experiments 
- = No increase observed when compared to untreated control 
* = P< 0.05, ** = P< 0.01 
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Table 5: Mean ± SD of bleomycin induced increase in sub-G1% in haemangioma derived 
cells 
Bleomycin (mU/ml) Increase in sub-G1 °/o 
24 hours 48 hours 
1mU/ml 
10mU/ml 
100mU/ml 
lOOOmU/ml 
10000mU/ml 
1.65 ±2 .82 
14.33 ± 12.18 
0.15 ±0.43 
0.97 ± 0.90 
9.69 ± 14.35 
18.74 ± 15.77 
^Data from three independent experiments 
- = No increase observed when compared to untreated control 
Table 6: Mean ± SD of bleomycin induced increase in sub-G1% in venous malformation 
derived cells 
Bleomycin (mU/ml) Increase in sub-GI %^ 
24 hours 48 hours 
ImU/ml 
lOmU/ml 
lOOmU/ml 
lOOOmU/ml 
lOOOOmU/ml 
0.13± 0.14 
0.24 ± 0.18 
0.38 ± 0.43 
0.79 ±0.15** 
4.89 ± 0.85** 
0.23 ±0.14 
0.24 ± 0.09 
4.32 ± 0.77** 
13.75± 3.39* 
^Data from three independent experiments 
- = No increase observed when compared to untreated control 
** = P< 0.01 
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Figure 3.6(a&b) Sub-Gl analysis of cell lines in the presence or absence of bleomycin. This data 
shows that the effect on HUVEC cells appears to be maximally effective within 24 hours, however all 
other cell lines show an increase in percentage of cells in sub-Gl fraction 24 hours later. 
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3.2.4 Detection of DNA fragmentation by flow cytometry using APO-DIRECF" 
Kit 
Inducfion of DNA strand breaks was determined using APO-DIRECT ™, by labelling 
DNA breaks with FITC-dUTP. Non-apoptofic cells were idendfied as a negafively 
stained population, whereas apoptofic cells incorporate the FITC-dUTP and are 
idenfified as a positively stained populafion. Following experiment 3.2.3, an increase in 
sub G l % was observed for all cells at a dose of 10,000mU/ml 24 hours post treatment. 
Therefore the decision was made to use this dose and time point for the subsequent 
experiments. All cells were assayed after 24 hours incubafion in the presence or absence 
of 10,000mU/mI bleomycin. Results confirmed the induction of DNA strand breaks in 
all cell lines after treatment with bleomycin (figure 3.8). An approximately 9-fold 
increase (1.83 ± 0.53 to 16.90 ± 1.98) in FITC-dUTP-positive keloid derived cells was 
observed after bleomycin treatment. Haemangioma derived cells showed an 
approximately 6-fold increase (1.85 ± 0.32 to 11.06 ± 1.10), an approximately 4-fold 
increase was observed in HUVEC (4.91 ± 0.24 to 21.32 ± 3.56) and foreskin fibroblasts 
showed an approximately 5 fold increase in FITC-dUTP-posifive cells (1.79 ± 0.24 to 
21.32 ±3.56). 
Bleomycin induced DNA strand breaks were calculated as (FITC-dUTP-positive cells 
% in the presence of bleomycin - FITC-dUTP-positive cells % in the absence of the 
drug). The percentage of bleomycin induced DNA strand breaks for the keloid and 
haemangioma derived cells and HUVEC cells were compared to that of the foreskin 
fibroblast (figure 3.8(b)). Both keloid derived cells and HUVEC cells were shown to 
have a significantly higher inducfion of DNA strand breaks after treatment with 
bleomycin than that of the foreskin fibroblasts (P= <0.01). Bleomycin induced DNA 
strand breaks in haemangioma derived cells were not considered to be statistically 
significantly different to that of the foreskin fibroblast (P= > 0.05). 
As described earlier (1.1.1), one of the reported mechanisms of bleomycin cytotoxicity 
is direct DNA binding resuldng in single and double-strand breaks. To determine 
whether the DNA strand breaks detected by the APO-DIRECT™ kit were independent 
of apoptosis, a fiirther assay was performed using an anfibody for cleaved caspase-3, a 
key mediator in mammalian cell apoptosis. 
27 
Results 
I -
Control (OmU/ml bleomycin) 
M l =98.17% 
M 2 = 1.83% 
fa-haft 
M2 
• " I - I I I I 11 
10* 
FLl-Height 
I 
Treated (lO.OOOmU/ml bleomycin) 
M l =83.10% 
M 2 = 16.90% 
FLl-Height 
Figure 3.7 Induction of DNA breaks on keloid derived cell line as detected by F I T C -
dUTP labelling and analysed by flow cytometry. 10,000 cells were analysed per 
determination. Al l cells were incubated for 24 hours, in the presence or absence of 
10,000mU/ml bleomycin. The data was plotted onto a FLl histogram and the percentage of 
FITC-dUTP positive cells was determined. A l l experiments were performed n=3. Typical flow 
cytometry histograms in a representatiye experiment are presented above. 
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Figure 3.8 Bleomycin induction of DNA strand breaks as determined by FITC-dUTP 
labelling. Cells were incubated in the presence or absence of 10,000mU/ml bleomycin for 24 
hours and assayed by flow cytometry using APO-DIRECT TUNEL method (a) The results are 
expressed as % of FITC-dUTP-positive cells and are given as the mean ± SD for 3 
experiments, (b) Bleomycin induced increase in DNA strand breaks. The data from (a) is 
expressed as absolute increase in % FITC-dUTP labelled cells compared with untreated cells. 
Compared with foreskin fibroblasts, the other three cell types showed an greater increase in 
DNA labelling, which was statistically significant in the case of keloid and HUVEC ** = P< 
0.01. 
Results 
3.2.5 Detection of apoptosis by intracellular staining using cleaved caspase-3 
conjugated antibody 
Caspase-3 cleavage was determined using cleaved caspase-3 conjugated antibody. All 
cells were assayed after 24 hours incubation in the presence or absence of 10,000mU/ml 
bleomycin. Results confirmed the activation of caspase-3 in the keloid derived cell line 
after treatment with bleomycin (figure 3.9(a)); an approximately 5-fold increase in 
cleaved caspase-3 positive cells was observed (5.54 ± 2.04 to 26.53 ± 1.96). The 
percentage of cleaved caspase-3 positive cells in the foreskin fibroblast cells did not 
increase significantly following treatment with bleomycin (4.17 ± 0.66 to 5.60 ± 1.02). 
Bleomycin induced caspase-3 cleavage was calculated as (cleaved caspase-3 posifive 
cells % following treatment with bleomycin - cleaved caspase-3 positive cells % in the 
absence of the drug). The percentage of bleomycin induced caspase-3 cleavage for the 
keloid derived cell line was compared to that of the foreskin fibroblast (figure 3.9(b)). 
Results from this assay showed that keloid derived cells had a significantly higher 
inducfion of caspase-3 cleavage following treatment with bleomycin than that of the 
foreskin fibroblasts (P = <0.01). 
28 
Results 
26.53 
(/) 25 
! Control (OmU/ml) 
l10000mU/ml 
4.17 
T 
Keloid Foreskin Fibroblast 
W 15 
Keloid Foreskin Fibroblast 
Figure 3.9 Effects of bleomycin on caspase-3 cleavage. Cell lines were incubated in the 
presence or absence of 10,000mU/ml of bleomycin for 24 hours, and caspase-3 cleavage 
determined by binding of specific fluorescent antibody. The results are expressed as (a) 
Percentage of cells showing specific antibody binding in the presence or absence of bleomycin 
and (b) the percentage increase following bleomycin treatment. Results are expressed as the 
mean ± SD for 3 experiments. ** = P< 0.01 Keloid cells showed a statistically significant 
greater sensitivity to bleomycin compared with foreskin fibroblasts. 
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Chapter 4 
4 Discussion 
This study investigated the effects of bleomycin on a range of human primary cell lines 
derived from haemangioma, venous malformation and keloid scars. Observations from 
dose responsiveness of these derived cell lines along with other control cell lines 
(foreskin fibroblast, HUVEC, HMEC-1) in vitro subsequently led this study to focus on 
possible mechanisms involved in bleomycin-induced cell death in these cells. It 
demonstrates for the first time that, in keloid derived cells, bleomycin-induced cell 
death is associated with caspase-3 mediated apoptosis. 
The mechanism of action of bleomycin in clinical cases of haemangioma, venous 
malformafion and keloid is not yet described. The aim of this study is to improve our 
understanding of the mechanism by which bleomycin exerts its effects, which could 
uhimately lead to the identification of an alternative therapeutic strategy which could 
avoid the substantial side effects of this powerful cancer chemotherapeutic. 
The first component of this was to establish an in vitro system. In order to derive the 
primary cell lines required for this, tissues were cultured as explants of small fragments 
or as single cell cultures following collagenase digestion. Although the latter approach 
offers the opportunity for both adherent and non-adherent cell types to grow out, no cell 
lines developed. However, adherent cell lines were successfully derived from explant 
cultures of all three tissue types. The cell lines obtained from haemangioma explants 
had a fibroblast-Iike morphology, a result consistent with other studies of explant-
derived cell types from haemangioma. Yu et al. (2006) isolated cells from both 
proliferating and involuting haemangiomas using an adherence technique and described 
these to have a fibroblast-like morphology. Using the same method they also attempted, 
unsuccessftilly, to isolate adherent cells from other skin abnormalities. However, in this 
study we managed to isolate cells not only from haemangioma tissue, but also from 
venous malformation and keloid scars. The cells obtained from keloid and venous 
malformation explants also had a fibroblast-like morphology, which is not surprising as 
the mode of selection used in this study invites similar cell types out of these tissues. 
The fibroblast-like morphology of the keloid derived cells described in this work is in 
agreement with other published works using the explant culture technique (Babu et al. 
1989; Chodon et al. 2000; Cheng et al. 2001). Given the similarity in gross cellular 
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morphology, one possibility is that that an identical cell type has been isolated from all 
three fissues by virtue of this culture method. I f this were the case, then these three cell 
lines should show a similar sensitivity to bleomycin. This proved not to be the case. 
Dose response studies were performed on cell lines derived from tissue specimens 
(haemangioma, venous malformadon, and keloid) along with other cell lines (foreskin 
fibroblasts, HUVEC, HMEC-1) and showed that at a dose of lOOmU/ml bleomycin, all 
cell lines demonstrated a Gl arrest after 48 hours in culture. Whilst this is in agreement 
with Gonzales et al. (1998) whose work also described a Gl arrest in response to 
bleomycin freatment in mouse hepatocytes, in fact most studies into the effect of 
bleomycin on cells in vitro have reported an arrest in the G2 fraction of the cell cycle. 
Barranco et al. (1971) showed that bleomycin treatment caused G2 arrest in Chinese 
hamster ovary cells (CHO); this was later confirmed by Tobey (1972) who showed that 
bleomycin had little effect upon DNA synthesis in CHO cells, but was extremely 
effective in the irreversible prevention of cells progressing from G2. Barlogie et al. 
(1976) and Bell et al. (1988) also described a concentrafion dependent accumulafion of 
human lymphoma cells and human osteosarcoma cells respectively, in the G2 fraction 
of the cell cycle. Tounekti et al. (1993) also described a G2 arrest in Chinese hamster 
lung fibroblasts following exposure to low concentrations of bleomycin. More recently, 
Arai et al. (2004) noted a G2 arrest in a human T-cell leukaemia cell line following 
treatment with bleomycin; however this study also investigated the effect of bleomycin 
on HUVEC cell line and reported that bleomycin induced both Gl and G2 arrest in 
these cells. Future work could include experiments to determine i f the Gl arrest 
observed in the cell lines in this study is reversible, by stopping the treatment after a 
certain time point and measuring the Gl/S rado after allowing the cells time to recover. 
Following DNA damage, cells ensure that mutations are not passed on to their daughter 
cells by either arresting the cell cycle to allow fime for DNA repair, or DNA damaged 
cells which cannot be repaired can be eliminated by apoptosis (Di Leonardo et al. 
1994). I f bleomycin at a concentration of lOOmU/ml was arresting the cells following 
DNA damage, then it would be fair to assume that treatment with higher doses of 
bleomycin would lead to greater DNA damage and chromosomal breakup. Results in 
the present study showed that bleomycin induced a dose-dependent increase in sub-Gl 
population in all the cell lines treated, which is a specific marker of apoptosis. Dose 
dependent bleomycin-induced increase in sub-Gl percentage has also been described in 
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work by Wallach-Dayan et al. (2005) when working with mouse lung epithelial cells 
and by Chen et al. (2004) when working with human liver carcinoma cells. 
Although all cells appeared to have a similar dose-dependent response to bleomycin, 
ftirther analysis showed that there was a differential sensitivity between cell types to the 
drug. Endothelial cell lines HUVEC and HMEC-1 appeared to be the most sensitive to 
bleomycin, showing a greater increase in sub-Gl percentage after 24 hours treatment 
with bleomycin than the other cell lines treated. However differences between these two 
cell lines became apparent after a fiirther 24 hours incubation in the presence of 
bleomycin. While the percentage of sub-Gl cells continued to increase in the HMEC-1 
cells following 48 hours in the presence of bleomycin, HUVEC sub-Gl percentage did 
not increase significantly when incubation time was increased. This suggests that the 
effect of bleomycin on HUVEC cells is maximal within 24 hours. Differential 
sensitivity was also observed in the keloid cells when compared to foreskin fibroblasts, 
with results suggesting that keloid cells were more susceptible to bleomycin treatment. 
One explanation of these results could be that the differences observed between cell 
lines are due to differential uptake. It is thought that the action of bleomycin on 
neoplastic cells is largely dependent on intemalisation (Heller et al. 1998). 
Electroporation is one mechanism that can be used to enhance intemalisation of 
bleomycin. Previous work by Tounekti et al. (1993) has shown that bleomycin 
cytotoxicity increases in vitro following electroporafion of Chinese hamster lung 
fibroblasts. Orlowski et al. (1998) also described a 700-fold increase in toxicity of 
bleomycin in the same cell line following electropermeabilisation. Further work to this 
study could include the electropermeabilisation of all the cell lines, to determine 
whether there are still detectable differences in sensitivity when the same concentration 
of bleomycin is introduced to the cytoplasm. Another method to assess whether 
differential uptake is the reason behind the differential sensitivity observed in these cell 
lines is the use of a bleomycin-specific antibody. Staining cells post-treatment with this 
antibody could allow identification of the cells which have internalised the drug. 
Differential sensitivity to bleomycin has also been linked to a cells ability to inactivate 
bleomycin. Work by Umezawa et al. (1972) discovered that cells of both the lungs and 
skin were deficient in their ability to inactivate bleomycin. Bleomycin can be 
metabolised by a cystein peptidase termed bleomycin hydrolase. Bleomycin hydrolase 
acts on the carboxamide group of the B-aminoalanine moiety in bleomycin to render an 
inactive metabolite (Umezawa et al. 1972). Further studies, including in vivo and in 
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vitro work by Lazo et al. indicated that the sensitivity of the lungs to bleomycin induced 
toxicity could be due to the lack of bleomycin hydrolase activity (Lazo et al. 1983). 
Yeast strains expressing high levels of bleomycin hydrolase were shown to be more 
resistant to bleomycin compared with wild-type controls (Kambouris et al. 1992). Jn 
vivo work using a mouse model that completely lacked any detectable bleomycin 
hydrolase activity showed that Bh -/- mice were hypersensitive to bleomycin, displaying 
pulmonary fibrosis or lethality in response to doses of bleomycin which in Bh +/+ mice 
showed no effect (Schwartz et al. 1999). These results strongly suggest the protective 
role bleomycin hydrolase plays against bleomycin induced toxicity; therefore it would 
be interesting to assess the expression of bleomycin hydrolase in the cell lines treated in 
this study, to determine whether differential expression correlates with cell sensitivity. 
Both haemangioma and venous malformation derived cells showed a similar dose and 
time course sensitivity; however there was far greater variance between samples in 
haemangioma derived cells. Due to the non-selective nature of the derivation of cells 
from the haemangioma tissue using explant culture, it would not be unreasonable to 
suggest that the population of cells obtained from these tissue specimens were 
heterogeneous. From the results obtained, it would appear that there are cells within this 
population which are uniquely sensitive to bleomycin. Recent work by Khan et al. 
(2008) identified a haemangioma stem cell (Hem-SC) which when implanted into 
immunodeficient mice were shown to recapitulate haemangioma-like lesions. From this 
work they concluded that Hem-SCs were likely to be the cellular origin of 
haemangioma. One could hypothesise that this stem cell population could be the 
bleomycin-sensitive cell type seen in the haemangioma derived cell line in this study. 
One approach to answering this question would be to characterise the cell lines 
described in this work with the Hem-SC, using cell surface marker expression, secretion 
of paracrine growth factors and gene expression profile. This data would help address 
whether the nature of the cells is biologically similar. However, the best approach 
would be to directly examine the bleomycin sensitivity of Hem-SC in the assays 
described here. 
Apoptosis was detected by the TUNEL method, to determine whether the bleomycin 
induced sub-Gl population observed in the previous experiments were in fact cells with 
detectable DNA strand breaks seen in apoptotic cells, and not merely mechanically 
damaged cell fragments. This assay confirmed bleomycin-induced DNA strand breaks 
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in all four cell lines treated. As with the previous assay, differential sensitivity was 
observed between cell lines, with HUVEC displaying the greatest induction of DNA 
strand breaks following treatment with bleomycin. There also appeared to be a clear 
difference in bleomycin-induced DNA strand breaks in keloid derived cells when 
compared to normal foreskin fibroblast cells, with keloid derived cells showing almost 
double the DNA damage. Although the cells derived from keloid tissue are likely to be 
fibroblasts; as based on their appearance in culture and the cellular nature of keloid 
scars, these cells are clearly more sensitive to bleomycin than normal foreskin 
fibroblasts. 
One possible explanation of the results presented in this study is that the difference 
between these cells lines is genetic; that the individual from whom the keloid scar fissue 
was obtained is simply genetically more susceptible to the effects of bleomycin. One 
way to validate this theory would be to obtain normal tissue from patients presenting 
with keloid scars, as well as from the keloid scars themselves. It would then be possible 
to assess any differences in response to bleomycin between normal fibroblasts and 
keloid fibroblasts from the same patient, although performing such a study would carry 
significant ethical problems, as the aim of most reconstructive surgery is to preserve, 
rather than resect, normal tissue. Ethical limitations in this study meant that this was not 
possible, as only tissue from the lesions could be removed. Furthermore, clinical studies 
to date have demonstrated the near universal sensitivity of these lesions to bleomycin 
treatment, suggesting an intrinsically higher sensifivity, and whilst there is evidence of 
bleomycin resistance at a cellular level due to hydrolase expression, it has not been 
described at the level of the whole individual. 
As described earlier in the results (3.2.4), an antibody specific for cleaved caspase-3 
was used to determine whether the bleomycin-induced sub-Gl population and DNA 
strand breaks observed in the previous experiments were due to apoptosis and not 
simply direct DNA binding by bleomycin resuUing in DNA strand breaks. Both keloid 
derived cells and foreskin fibroblasts showed a bleomycin-induced activation of 
caspase-3, however the level of caspase-3 cleavage was significantly greater in keloid 
derived cells. To the best of our knowledge, this is the first report of caspase-3-mediated 
apoptosis of keloid derived cells induced by bleomycin. 
Bleomycin is known to degrade DNA and creates single and double strand breaks in 
neoplastic cells (Suzuki et al., 1969; Miyaki et al., 1975; Kohn et al., 1975), effects 
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which are presumed to be responsible for bleomycins chemotherapeutic properties. 
However there is emerging evidence that bleomycin may act through other pathways. 
As mentioned earlier, the main dose-limiting effect of bleomycin is pulmonary toxicity, 
resulting in pulmonary fibrosis. Extensive in vivo and in vitro research has been 
performed to try and determine the mechanism by which bleomycin induces pulmonary 
fibrosis, yielding interesting results. An in vitro study by Wallach-Dayan et al. used 
murine lung epithelial cells to invesfigate bleomycin-induced apoptosis of lung 
epithelial cells. Their results showed that bleomycin caused reactive oxygen species 
(ROS) accumulation, increased caspase activity, apoptosis and increased expression of 
cell surface Fas/FasL. Apoptosis was shown to be inhibited by glutathione, but not by 
Fas/FasL pathway antagonists; suggesting that bleomycin functions via ROS-induced 
mitochondrial cell death and that the Fas/FasL pathway is not predominant (Wallach-
Dayan et al. 2006). In vivo, treatment with antioxidant amifostine was shown to 
significantly attenuate bleomycin-induced lung injury in a hamster model, providing 
ftirther evidence of ROS involvement in bleomycin-induced lung injury (Nici et al. 
1998). It is possible that bleomycin may exert its effects on the lesions examined in this 
study by the same process. Future work could include the assessment of ROS 
accumulation in these cell lines. 
Growing evidence suggests that transforming growth factor- B (TGF-13) is important in 
the process of bleomycin-induced pulmonary fibrosis. TGF-B pulmonary levels were 
shown to be elevated in mice (Hoyt et al. 1988) and in rats (Westergren-Thorsson et al. 
1993) following intracheal bleomycin installation. Administration of an antibody to 
TGF-B (Giri et al. 1993) and a receptor antagonist for this cytokine (Wang et al. 1999) 
have been shown to attenuate bleomycin-induced pulmonary fibrosis. Inhibition of 
activin receptor like kinase-5 (ALK5), a type 1 TGF-6 receptor, has also been shown to 
attenuate bleomycin-induced pulmonary fibrosis (Higashiyama et al. 2006). 
An important effect of TGF-B is induction of apoptosis. This has been demonstrated in 
human lung epithelial cells by Yanagisawa et al. (1998) when cultured in the presence 
of TGF-B, these cells showed a marked induction of apoptotic cell death. TGF-B has 
also been shown to enhance Fas-mediated apoptosis of lung epithelial cells via caspase-
3 activation (Hagimoto et al. 2002). 
Previous work by Kuwano et al. (1999) demonstrated the importance of the Fas-Fas 
ligand pathway in the development of bleomycin-induced pulmonary fibrosis. Fas 
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ligand (FasL) is a cell surface molecule belonging to the TNF family. When FasL binds 
to its receptor Fas, it induces apoptosis of Fas-bearing cells (Kuwano et al. 1999). 
Bleomycin administration in an animal model for pulmonary fibrosis resulted in an 
upregulation of FasL mRNA in infiltrating lymphocytes and an upregulation of Fas 
mRNA in alveolar epithelial cells (Hagimoto et al. 1997). Kuwano and colleagues 
showed that the administration of a soluble form of Fas antigen prevented apoptosis of 
epithelial cells and subsequent development of fibrosis. 
Caspase activation is required for cell death via the Fas-FasL pathway. This fact led 
Kuwano et al. to examine the possibility that caspase inhibitors may prevent Fas-FasL 
mediated bleomycin-induced pulmonary fibrosis. Using the caspase inhibitor (Z-VAD-
FMK) Kuwano et al. demonstrated it decreased the number of apoptotic cells, reduced 
caspase activity in general and decreased the pathological grade of lung inflammation 
and fibrosis. Similar work by Wang et al. confirmed the effectiveness of the caspase 
inhibitor Z-VAD-FMK to attenuate bleomycin-induced lung fibrosis by abrogation of 
alveolar epithelial cell apoptosis (Wang et al. 2000). 
Although the Fas-FasL pathway was shown to be required for bleomycin-induced 
pulmonary fibrosis in mice, some mice deficient in either Fas or FasL developed mild 
disease; suggesting that other death receptors or death signals such as reactive oxygen 
species may be involved (Kuwano et al. 2001). 
TGF-13 has also been shown to downregulate the synthesis of cyclin-dependent kinase 4 
(cdk4), a cdk involved in Gl checkpoint, resulting in Gl arrest in murine lung epithelial 
cells (Ewen et al. 1995). It is interesfing that two of the observed effects of bleomycin in 
this study (Gl arrest and caspase-3 mediated apoptosis) have been described in previous 
studies as the subsequent effects of TGF-6. It may be that bleomycin is acting via TGF-
6 signalling in the cell lines examined in this study. Future experiments to assess the 
involvement of TGF-B in bleomycin cytotoxity could include the administration of an 
antibody to TGF-B, or inhibition of the related effector molecules (caspase-3, Fas) to 
determine any downregulation in apoptosis. Also expression levels of TGF-6, p53 and 
Fas in these cells following treatment with bleomycin would also help determine the 
signalling pathways involved. 
In conclusion, results fi-om this study show that bleomycin induces apoptosis of 
haemangioma, venous malformation and keloid derived cells in a dose dependent 
manner. In addifion, we also report for the first fime that bleomycin induces a caspase-3 
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mediated apoptotic cell death in keloid derived cells. This work is novel in showing 
caspase-3 acfivation in keloid derived cells following treatment with bleomycin, and 
provides the basis for further investigations, both in vitro and in vivo, that will confimi 
whether this mechanism is responsible for the apoptosis obsei-ved in the other lesions 
discussed whilst further elucidating the intracellular processes involved. The use of 
bleomycin for these common lesions is currently restricted to specialist clinical units 
and remains limited by its potential toxicity in these young patients. It is, however, very 
effecfive and it is only through further understanding of its acHons that a less toxic 
altemafive can be found. 
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Appendix 1: Chapter 2 
Tissue culture 
Endothelial cel l growth medium MV ( H U V E C media) 
After adding the attached supplement mix the media contains: 
Endothelial Cell Growth Supplement/Hepar in: 0.004ml/ml medium 
Epidermal Growth factor, human recombinant: 10.0ng/ml medium 
Hydrocort isone: 1.0|jg/ml medium 
Phenol Red: 0.62ng/ml medium 
Foetal Calf serum: 0.05ml/ml medium 
Growth media for HMEC-1 cel ls 
MCDB-131 growth medium containing 10% FBS, lOng/ml human epidermal 
growth factor (EGF), 1[jg/ml hydrocort isone, 50Mg/ml gentamycin and 250| jg/ml 
amphotericin B. 
Growth media for haemangioma, venous malformation and keloid derived 
ce l ls 
Minimum essential media (MEM) containing 2 0 % (v/v) foetal bovine serum, 
2 m M L-glutamine, 50| jg/ml gentamycin solution and 250| jg/ml amphotericin B. 
Growth media for foreskin f ibroblasts 
MEM supplemented with 10% (v/v) FBS, 2 m M L-glutamine, 50Mg/ml 
gentamycin and 250pg/ml amphotericin B. 
Double strength antibiotic Media 
Minimum essential media (MEM) containing 2 0 % (v/v) foetal bovine serum, 
2 m M L-glutamine, lOOpg/ml gentamycin solution and 500|jg/ml amphotericin B. 
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Appendix 2: Chapter 2 
Manufacturers 
BD Fa lcon 
Web address of supplier: www, bdbiosciences. com 
G i b c o 
Web address of supplier: www, in vitroaen. com 
Greiner 
Web address of supplier: www, greinerbioone. com 
H a u s s e r Scientif ic 
Web address of supplier: www, hausserscientific. com 
Nunc 
Web address of supplier: www, nuncbrand. com 
Promocel l 
Web address of supplier: www, promocell. com 
Sigma-Aldr ich 
Web address of supplier: www, siamaaldrich. com 
Worthington 
Web address of supplier: www, worthinaton-biochem.com 
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Appendix 3: Chapter 2 
Ethical Approval 
Bleomycin and the cell biology of benign skin lesions 
P R O T O C O L 
Background: 
Juvenile haemangioma is the commonest tumour of childhood, but remains poorly understood. It usually 
forms a small, pink lesion in the skin and is often considered to be a birthmark. It typically appears a few 
weeks after birth and grows for a period of time (the proliferative phase), remains unchanged for a 
variable period of time and then shrinks (regression phase) to subsequently disappear completely. 
Although the vast majority of cases regress spontaneously as described and cause no permanent 
problems, a significant proportion, usually due to their size or position, require more intensive 
intervention. 
Treatment with surgery and corticosteroids are the typical treatment options but the results can be 
disappointing. More recently it has been recognised that bleomycin, a chemotherapeutic agent, when 
injected into these lesions can cause them to shrink dramatically. This has led to use of bleomycin in 
other challenging skin disorders, including arteriovenous (AV) malformations and keloid scars, as well as 
malignancies including metastatic malignant melanoma. Cutaneous AV malformations encompass a 
range of lesions, including cystic hygroma, which is thought to represent an overgrowth of lymphatic 
vessels. It is regarded as a benign tumour, but can be challenging to treat. It frequently recurs after 
surgery, and other therapeutic options are limited, although it does appear to respond well to intra-lesional 
bleomycin therapy. Keloid is a very common condition, and is a benign, but potentially disfiguring 
overgrowth of tissue related to a scar. Again, surgery is an imperfect treatment option, with high 
recurrence rates, and as with the other lesions, there is growing evidence that the injection of bleomycin 
can lead to regression. 
Bleomycin is a well known, frequently used but relatively toxic agent, pulmonary fibrosis being its most 
significant side effect. It is most often used in the treatment of various lymphomas and testicular 
carcinomas, where its mechanism of action is probably through DNA cleavage in the dividing cancer 
cells. However, there is some evidence that it may also act through other pathways; how it acts in these 
skin lesions is unknown. Given its toxicity, we wish to explore further its action in these lesions at the 
level of cell signalling, with the ultimate aim of determining whether other, less toxic, compounds, may 
be able to act in a similar way with the same therapeutic effect. 
The plastic surgery unit at the James Cook University Hospital is one of the few in the country where 
such bleomycin treatment is available. As a tertiary referral centre for these challenging problems, it also 
receives a substantial number that still require excisional surgery, generating tissue that would otherwise 
be discarded, that could be used to investigate these conditions ftjrther. 
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Aims and objectives: 
1. Establish cell lines from juvenile haemangioma, cutaneous AV malformations and keloid lesions. 
2. Determine their relative sensitivity to bleomycin in vitro, and in comparison to banked cell lines 
representative o f norma) skin components. 
3. Determine the mode of action of bleomycin in the cells. 
Summary of procedures: 
1. Retrieving tissue. 
Patients admitted for excision of juvenile haemangioma, AV malformations and keloid, either for 
therapeutic or diagnostic reasons, will be prospectively identified from waiting lists and at assessment at 
specialist clinics. They (and their family) will be approached by the consultant plastic surgeon to discuss 
the study and obtain informed consent. The vast majority of patients with haemangiomas wil l be under 5 
years old, as such, consent to retrieve surplus tissue will be obtained from their parent or legal guardian 
when consent for the surgical procedure itself is obtained. 
Tissue will be obtained at the time of surgery. The majority of specimens wil l be placed in cold, sterile 
buffer solution, labelled with the age and sex of the patient, anatomical location of the lesion and the 
clinical diagnosis. For juvenile haemangioma, the specimen will also be labelled to indicate whether it 
was felt to be in the proliferative or regression phase at the time of excision (the vast majority are likely to 
be in the proliferative phase). The specimen will also be labelled to indicate i f there has been prior 
therapy with bleomycin. In some instances, where there is a need to extract RNA or perform particular 
histological assessment techniques, the lesion will be frozen immediately at the time of excision 
otherwise they will be refrigerated at 4C. 
To further ensure anonymity, the consultant plastic surgeon ordinarily responsible for the care of the 
patient will maintain a database of patients from whom tissue is obtained. This wil l enable all specimens 
to be labelled with a unique identifier, as well as the information outlined above, the database will link the 
unique identifier with the patient's hospital number, and will be stored only on NHS systems for the 
duration of the study. 
The tissues will be transferred to the laboratories at Durham University within 24 hours of retrieval. 
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2. Establishing cell lines. 
The lesions will be dissected free from normal surrounding tissues and further dissociated by enzymatic 
treatment. Primary cultures will be established in standard culture conditions, and clonal cell populations 
derived from these. Similar protocols will be followed for all the lesion types, with variations only in the 
enzymatic treatment regimens. 
Experimental strategies: 
1. Characterisation of cell lines. 
After the establishment of primary cultures, cell lines thus derived will be characterised by 
immunohistochemistry and DNA analysis to determine the expression of published markers associated 
with the pathological lesions. We will also seek to determine i f they express markers consistent with 
stem cell, vascular and other skin phenotypes. Frozen specimens will be used for the extraction of RNA. 
Their ability to grow in both 2-D and 3-D cultures will be examined and compared to that of cell lines 
representative of the components of normal skin. 
2. Response to bleomycin 
Bleomycin will be added to cultures derived from the lesions, as well as cultures of normal 
dermal cells, epithelial cells, endothelial cells and dermal stem cells. Any effect on cell death 
(particulady apoptosis) or replication will be examined at varying concentrations of the agent to 
determine i f there is any difference in sensitivity between cell types. Various inhibitors of known 
apoptotic signalling pathways will be used in an attempt to determine the signalling pathways involved, 
and the results from these initial experiments will inform further examination of the signalling pathways 
within the cells. 
3. Evaluation of alternative agents 
I f analysis of the signalling pathways involved suggests other potential therapeutic agents, these 
will be tested in vitro in a similar manner to the initial protocols. There is no intent to move to the 
clinical trial stage in this study. 
4. Co-culture 
In an attempt to further understand the mechanism of development of the lesions, cells derived 
may be co-cultured with other cell types, including stem cells, in an attempt to clarify any inductive 
capability of the tumour cell lines themselves. 
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South Tees Hospitals 
NHS Trust 
Chairman, Northumberland REC 
Room 144 TEDCO Business Centre 
Viking Industrail Park 
Rolling Mi l l Road 
Jarow 
NE 32 3DT 
19" Nov, 2007 
Department of Cardlothoracic Surgery, 
James Cook University Hospital, 
Marton Road, Middlesbrough 
TS4 3BW 
Tel: 01642 854728 
Email: andrew.owens@stees.nhs.uk 
Mr W Andrew Owens 
MB BCh BAO(Hons), MD, FRCSI , FRCS(CTh) 
Consultant Cardiothoracic Surgeon and 
Honorary Reader Reference number 07/H0902/56: A 
characterisation of the cell types within 
juvenile haemangioma, arterio-venous malformations and keloid, and the cellular response to 
bleomycin therapy. 
Dear Sir, 
Thank you for your letter of the 13th November regarding the recent REC meeting where the 
above study was discussed. 
Two issues requiring further clarification were highlighted in the letter: 
1. Anonymity -1 can confirm that the patients from whom tissue is obtained cannot be identified by any 
of the researchers. However, as a record of tissue obtained has to be kept for the duration of the study, 
and there is a theoretical possibility that the PI could identify the patient from a hospital number, the 
plastic surgeon performing the procedure will label each sample with a unique identifier. This will be 
generated by sequential numbering of specimens obtained, the plastic surgeon will maintain a database of 
the unique identifiers, linking them to hospital number, on the NHS computers that currently hold a 
database already in existence for these patients. Neither the PI nor any other researchers will have any 
access to this database. The protocol has been amended accordingly. 
2. Question A66 - we apologise that the student undertaking the MSc involved in this work was not 
properly identified. The candidate appointed to the post is Miss Lisa Clarke, who holds a BSc (2.1) in 
Biological Sciences. She will be based at the School of Biological and Biomedical Sciences, Durham 
University, under the supervision of Dr Nicholas Hole, as outlined in the original application. 
Further to the instructions of Verity Eggelston, the protocol has been amended and is attached, labeled 
version 2, 16'" November 2007. 
Yours sincerely, 
Andrew Owens 
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Results: Flow cytometry histograms 
Control (OmU/ml bleomycin) 
M l (Gl) = 78.38 % 
M3 (S) = 7.52 % 
Treated (lOOmU/ml bleomycin) 
M l (Gl) = 80.71 % 
M3 (S) = 4.86 % 
Representative ceil cycle histograms of keloid derived cells. The cells were gated as described in 
2.6.4 and the gated data plotted as an FL2 histogram. To determine the percentage of cells in G l , 
G2, S and sub-Gl, the cells were defined by their individual peaks as M l , M2, M3 and M4 
respectively 
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Control (OmU/ml bleomycin) 
M l (Gl ) = 59.04% 
M3 (S)= 13.33% 
Treated (lOOmU/ml bleomycin) 
M l (Gl) = 71.59% 
M3 (S) = 3.84 % 
Representative ceU cycle histograms of H U V E C . The cells were gated as described in 2.6.4 and 
the gated data plotted as an FL2 histogram. To determine the percentage of cells in G l , G2, S and 
sub-Gl, the cells were defined by their individual peaks as M l , M2, M3 and M4 respectively 
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Control (OmU/ml bleomycin) 
M l (Gl) = 70.68% 
M3 (S)= 12.77% 
Treated (IQQmU/ml bleomycin) 
M l (Gl ) = 80.50% 
M3 (S) = 5.37 % 
Representative cell cycle histograms of haemangioma derived cells. The cells were gated 
as described in 2.6.4 and the gated data plotted as an FL2 histogram. To determine the 
percentage of cells in G l , G2, S and sub-Gl, the cells were defined by their individual peaks 
as M l , M2, M3 and M4 respectively 
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Control (OmU/ml bleomycin) 
M l (FITC-dUTP negative) = 98.21 % 
M2 (FITC-dUTP positive) = 1.79 % 
Treated (lO.OOOmU/ml bleomycin) 
M l (FITC-dUTP negative) = 91.55 % 
M2 (FITC-dUTP positive) = 8.45 % 
10* 
Induction of DNA breaks on foreskin fibroblast cells as detected by FITC-dUTP labelling 
and analysed by flow cytometry. 10,000 cells were analysed per determination. Al l cells 
were incubated for 24 hours, in the presence or absence of 10,000mU/ml bleomycin. The data 
was plotted onto a FLl histogram and the percentage of FITC-dUTP positive cells was 
determined. A l l experiments were performed n=3. Typical flow cytometry histograms in a 
representative experiment are presented above. 
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Control (OmU/ml bleomycin) 
M l (FITC-dUTP negative) = 95.09 % 
M2 (FITC-dUTP positive) = 4.91 % 
Treated qCOOOmU/ml bleomycin) 
M l (FITC-dUTP negative) = 78.68 % 
M2 (FITC-dUTP positive) = 21.32 % 
Induction of DNA breaks on H U V E C cells as detected by FITC-dUTP labeUing and 
analysed by flow cytometry. 10,000 ceils were analysed per determination. A l l cells were 
incubated for 24 hours, in the presence or absence of 10,000mU/ml bleomycin. The data was 
plotted onto a F L l histogram and the percentage of FITC-dUTP positive cells was determined. 
Al l experiments were performed n=3. Typical flow cytometry histograms in a representative 
experiment are presented above. 
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Control (OmU/ml bleomycin) 
M l (FITC-dUTP negative) = 98.15 % 
M2 (FITC-dUTP positive) = 1.85 % 
Treated (lO.OQOmU/ml bleomycin) 
M l (FITC-dUTP negative) = 88.94 % 
M2 (FITC-dUTP positive) = 11.06 % 
Induction of DNA breaks on haemangioma derived cell line as detected by FITC-dUTP 
labelling and analysed by flow cytometry. 10,000 cells were analysed per determination. Al l 
cells were incubated for 24 hours, in the presence or absence of 10,000mU/ml bleomycin. The 
data was plotted onto a F L l histogram and the percentage of FITC-dUTP positive cells was 
determined. Al l experiments were performed n=3. Typical flow cytometry histograms in a 
representative experiment are presented above. 
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Forskin Fibroblasts Cell cycle and apoptosis @ 48 hours 
100% 
1% apoptosis I 
l%S phase 
1% G2 
1% G1 
48 hour control 48hour1mU/ml 48hour10mU/ml 48hour100mU/ml 
Concentration bleomycin (mU/ml) 
Sample G1 G2 S phase Sub-G1 
Control (OmU/ml) @ 5 hours 56.96 + 3.75 25.84 + 1.71 15.86 ±4.32 1.65 ±1 .93 
1mU/ml @ 5 hours 51.31 + 7.18 28.34 ± 1.95 19.29 ±8 .13 1.41 ± 1.01 
10mU/ml @ 5 hours 51.18 + 6.86 29.09 + 2.05 18.47 ±6.35 1.67 ±0.50 
100mU/ml @ 5 hours 47.32 + 4.91 31.24 ± 3.31 18.38 ±6 .28 3.47 ±3.20 
Control (OmU/ml) @ 24 hours 65.47 ± 1.07 19.06 + 1.77 15.40 ± 1.01 0.50 ±0.47 
1mU/ml @ 24 hours 63.93 + 2.40 20.35 ± 1.07 15.24 ± 1.69 0.86 ±1.23 
10mU/ml @ 24 hours 64.24 + 1.16 20.47 ±1.85 14.98 ± 1.39 0.66 ± 1.01 
100mU/ml @ 24 hours 66.90 ± 2.38 19.85 + 3.09 12.85 ± 1.44 0.70 ±0.90 
Control (OmU/ml) @ 48 hours 72.96 ± 1.84 14.77 + 0.24 12.00 ± 1.22 0.54 ±0.75 
1mU/m l@48 hours 73.20 ± 0.46 15.37 + 0.24 11.42 ±0 .43 0.25 ±0.26 
10mU/ml @ 48 hours 73.20 ± 0.62 15.20 ± 1.33 11.43 ± 1.02 0.41 ±0.53 
100mU/ml @ 48 hours 77.88 ± 2.27 13.61 ± 0.89 8.04 ± 0.59 0.65 ±0.93 
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Keloid Cell cycle and apoptosis @ 48 hours 
100% 
B% apoptosis 
• %S phase 
• % G 2 
• %G1 
48 hour control 48hour1mU/ml 48 hour 10mU/ml 48 hour lOOmU/ml 
Concentration bleomycin (mU/ml) 
Sample G1 G2 S phase Sub-G1 
Control (OmU/ml) @ 5 hour^ 69.74 ±6 .67 20.25 ±5 .30 9.37 ± 2.05 0.84 ± 0.35 
1mU/ml @ 5 houi^ 67.38 ±1.85 21.95 ±2 .46 9.15 ± 1.75 1.26 ±0 .46 
lOmU/ml @ 5 hours 66.79 ±1.85 23.17 ±2.07 8.40 ±1 .10 1.79 ±1 .25 
lOOmU/ml @ 5 hours 67.43 ±1 .73 23.43 ± 1.87 8.17 ± 1.73 1.08 ±0 .56 
Control (OmU/ml) @ 24 hours 72.13 ±2.22 17.80 ±2 .13 9.69 ± 2.09 0.64 ± 0.56 
1mU/ml@ 24 hours 70.64 ±2.63 19.57 ±0 .35 9.72 ± 2.46 0.34 ± 0.22 
10mU/ml@ 24 hours 71.73 ±2 .56 19.11 ±0 .68 9.13 ±2 .38 0.29 ± 0.25 
100mU/ml@ 24 hours 76.74 ±1 .36 17.08 ± 1.53 5.97 ± 2.71 0.43 ± 0.31 
Control (OmU/ml) @ 48 hours 78.38 ±2 .16 14.51 ± 1.50 6.86 ±2 .56 0.45 ± 0.25 
1mU/mi@ 48 hours 78.86 ±2.76 14.47 ±1.91 6.27 ± 2.22 0.58 ± 0.44 
10mU/ml@ 48 hours 79.36 ± 3.28 14.03 ±2 .21 6.39 ±2.12 0.41 ± 0.30 
100mU/ml@ 48 hours 81.23 ± 1.07 14.20 ± 1.40 3.88 ± 1.87 0.78 ± 0.62 
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HUVEC cell cycle and apoptosis @ 48 hours 
100% 
B% apoptosis I 
• % S 
•%G2 
•%G1 
48 hour control 48hour1mU/ml 48hour10mU/ml 
Concentration bleomycin (mU/ml) 
48 hour 100mU/ml 
Sample G1 G2 S phase Sub-G1 
Control (OmU/ml) @ 24 hours 58.98 ±2 .91 27.97 ±2.23 10.72 ± 1.06 1.50 ± 0.43 
1mU/ml @ 24 hours 61.70 ±0 .94 25.02 ±0.68 9.99 ±1.21 1.60 ±0.42 
lOmU/ml @ 24 hours 60.45 ±2 .56 27.02 ± 0.24 9.32 ± 2.00 2.17 ±0 .50 
lOOmU/ml @ 24 hours 64.06 ± 1.24 27.25 ± 0.77 5.65 ± 0.48 2.58 ± 0.60 
Control (OmU/ml) @ 48 hours 59.04± 1.28 25.17±1.91 13 .33±2.26 2 .10±0 .30 
1 mU/ml @ 48 hours 58.79 ± 1.58 25.17 ±2 .33 13.08 ± 1.35 1.95 ±1 .26 
10mU/ml@ 48 hours 62.66 ±1 .19 24.23 ±2.94 10.86 ±1 .40 1.45 ±0.12 
100mU/ml@ 48 hours 71.59 ±0 .98 22.80 ± 0.38 3.84 ± 0.69 1.60 ±0 .21 
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Haemangioma cell cycle and apoptosis @ 48 hours 
|Q%apoptosis| 
'/o S phase 
yo62 
%G1 
48 hour control 48hour1mU/ml 48hour10mU/ml 
Concentration Bleomycin (mU/ml) 
48 hourlOOmU/ml 
Sample G1 G2 S phase Sub-G1 
Control (OmU/ml) @ 5 hours 68.48 ±4 .61 18.02 + 5.09 12.38 ±0 .61 1.48 ±1 .23 
1mU/m l@5hou rs 65.74 ±3 .90 19.38 ±6.06 14.12 ±1.60 1.31 ±0.90 
10mU/ml @ 5 hours 66.64 ±2.40 20.06 ±2.18 13.19 ±1 .25 0.44 ± 0.28 
lOOmU/ml @ 5 hours 64.94 ±2 .54 20.78 ±2 .21 13.71 ±0 .93 0.95 ± 0.54 
Control (OmU/ml) @ 24 hours 67.86 ±2.62 17.07 ±2.87 14.06 ±0.52 1.42 ±1.37 
ImU/ml @ 24 hours 67.51 ±0.40 18.39 ± 1.83 13.76 ±1 .98 0.69 ±0 .19 
10mU/ml@ 24 hours 69.64 ±1.42 17.29 ± 1.94 12.37 ± 1.62 1.07 ±0.68 
100mU/ml@ 24 hours 75.83 ±1.56 14.43 ±0.68 8.55 ±1.08 1.42 ±0.44 
Control (OmU/ml) @ 48 hours 70 .68±0.71 16.51 ±0 .81 12.77± 1.20 0.38 ± 0.23 
1mU/ml@ 48 hours 72.87 ±3 .10 15.37 ±0.59 11.79 ±2.45 0.28 ± 0.23 
10mU/ml @ 48 hours 68.49 ±10.53 15.01 ±1.18 15.97 ±9.55 0.53 ± 0.43 
lOOmU/ml @ 48 hours 80.50 ±2 .75 12.99 ± 1.05 5.37 ±1 .89 1.35 ±0.90 
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% Control apoptosis 
24 hours 48 hours 
Foreskin Fibroblasts 0.50 ± 0.47 0.48 ± 0.20 
HMEC-1 7.23 ± 0.62 6.03 ± 0.69 
Haemangloma 1.42 ± 1.37 0.38 ± 0.23 
Keloid 0.64 ± 0.56 0.45 ± 0.25 
Venous Malformation 0.74 ± 0.09 0.48 ± 0.09 
HUVEC 1.50 ±0.43 2.17 ±0.40 
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